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Abstract 
 
Computational methods for the prediction of G protein-coupled receptor (GPCR) 
structures were applied to serotonin receptors, and new methods were 
developed to predict an orphan GPCR structure.  First, the MembStruk 
procedure was used to predict the structures of the serotonin 2b and 2c 
receptors.  Ligand binding sites for agonists and antagonists were predicted for 
both receptors.  In addition, the SAR data for a series of psilocybin analogs 
bound to serotonin 2c were predicted.  There was good agreement with binding 
and mutagenesis experiments.  
 A new structure prediction procedure called SuperBiHelix was developed to 
predict an ensemble of low-lying structures.  SuperBiHelix samples the tilt and 
sweep angles of the transmembrane helices along with the rotation of the helices 
along the helical axes.  The procedure was validated on the β2-adrenergic 
receptor and A2A adenosine receptor crystal structures.  This procedure was then 
used to predict the structure of GPR88, an orphan receptor.  GPR88 has been 
identified as a novel target for psychiatric disorders.  Three lipids were predicted 
to bind to GPR88.  The head group of a lipid would bind to R113(3) and R116(3) 
at the extracellular side of the receptor.  The lipid tail would bind in an aliphatic 
pocket in the TM2-TM3-TM6-TM7 region. The predicted bound complexes offer 
good suggestions for binding and mutagenesis experiments that could help 
validate the proposed structures. 
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Introduction 
 
An important class of transmembrane proteins is the G protein-coupled receptor 
(GPCR) superfamily, which regulates signal transduction.  GPCRs are of great 
interest pharmacologically, for they are the targets of 50% of recently released 
drugs and 25 of the top 100 best-selling drugs.[1] Malfunctions in GPCRs play a 
part in diseases such as ulcers, allergies, migraines, anxiety, psychosis, 
schizophrenia, hypertension, asthma, congestive heart failure, Parkinson’s, and 
glaucoma.[2] Despite the great deal of interest in GPCRs, progress in obtaining 
atomic level experimental structures has been slow, due to challenges involved 
in GPCR expression, purification, and crystallization.  There are currently 
structures of only four GPCRs: rhodopsin,[3] the β1-adrenergic receptor,[4] the β2-
adrenergic receptor,[5] and the A2A adenosine receptor.[6] Consequently, there is a 
great need for GPCR structure predictions, which computational methods can 
help fill.  Many GPCRs have similar enough structures that an antagonist or 
agonist targeted at one receptor will bind another type of receptor and lead to 
unwanted side effects.  Thus, atomic-level structures are essential for the rational 
design of subtype-specific drugs.   
 The Membstruk procedure[2, 7] was used to successfully predict serotonin 2b 
and 2c structures and binding sites,[8] as described in Chapter 1.  The serotonin 
study led to some important developments in the method, most significantly the 
neutralization of complexes for binding energy calculations.  However, 
Membstruk required a great deal of user judgment.  Additionally, its results were 
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heavily dependent on the experimental template used because Membstruk 
sampled very little GPCR conformational space.  Thus, a new procedure, BiHelix, 
was developed that efficiently sampled all of the possible rotations of each helix 
around their helical axes.  This procedure was a big improvement over 
Membstruk, but it was still dependent on the experimental template used.  In 
order to predict the structures of receptors dissimilar to any available crystal 
structure, SuperBiHelix was developed.  SuperBiHelix samples the tilt and sweep 
angles of each helix in addition to the rotation around their helical axes.  The 
description and validation of SuperBiHelix is given in Chapter 2.  Finally, in 
Chapter 3, SuperBiHelix was used to predict the structure of the orphan GPCR 
GPR88.  An ensemble of low-lying GPR88 structures was predicted and some 
possible strong-binding lipids were proposed.  Ligand binding and mutagenesis 
experiments were suggested that could help to validate the proposed structures 
and binding sites. 
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Chapter 1 
 
The Structures of Human Serotonin 2b and 2c  
G Protein-Coupled Receptors Bound to Agonists 
and Antagonists 
 
 
Abstract 
We used the MembStruk computational procedure to predict the 3-dimensional 
(3D) structure for the serotonin 5-HT2C G protein-coupled receptor (GPCR).  
Using this structure, we used the MSCDock computational procedure to predict 
the 3D structures for bound ligand-protein complexes for agonists such as 
serotonin and antagonists such as ritanserin, metergoline, and methiothepin.  In 
addition, we predicted the SAR data for a series of psilocybin analogs, both 
agonists and antagonists.  We performed molecular dynamics (MD) on serotonin 
bound to 5-HT2C and we find the protein and binding site to be stable after 5 ns.  
We find good agreement with the currently known experimental data and we 
predict a number of new mutations, which could be used to validate further our 
predicted structures.  This agreement between theory and experiment suggests 
that our 3D structure is sufficiently accurate for use in drug design.  We also 
compare a preliminary prediction for 5-HT2B with our prediction for 5-HT2C and 
find a difference in TM5 that contributes to different serotonin binding modes in 5-
HT2B and 5-HT2C. 
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Introduction 
The serotonin (5-hydroxytryptamine, or 5-HT) class of G protein-coupled 
receptors (GPCR) serve as neurotransmitters involved in many processes in the 
central nervous system, including the regulation of feeding, aggression, mood, 
perception, pain, and anxiety.[9] Additionally, 5-HT regulates vascular and 
nonvascular smooth muscle growth, uterine smooth muscle growth, and 
gastrointestinal functioning.[9] Consequently, these receptors are targets for a 
variety of drug therapies.  This family of receptors that consists of at least 15 
receptors partitioned into seven main types helps to mediate these physiological 
functions.  This creates a problem for drug design since all 15 likely have similar 
binding sites, making it difficult to attain selectivity of a drug to just one receptor.  
This problem is made worse because there are no 3D x-ray structures for any of 
these receptors.  To help fill this gap we have been developing methods 
(MembStruk) for predicting the 3D structures. 
We consider here the 5-HT2 family, which consists of three structurally 
related receptors: 5-HT2A, 5-HT2B and 5-HT2C.  Drugs that target 5-HT2 receptors 
are used to treat such disorders as schizophrenia, depression, and glaucoma.  
The three 5-HT2 receptors have high sequence identity within the 
transmembrane domains, and they play a variety of physiological roles.  The 
majority of current drugs with affinity for 5-HT2 receptors are not subtype 
specific,[10] so it is often unclear which receptor is responsible for the particular 
physiological effect and which receptor is responsible for unwanted side effects.  
We expect that detailed knowledge of the ligand-binding environment of the 5-
 5 
HT2 receptors would facilitate the creation of more subtype specific drugs that in 
turn would lead to a better understanding of the specific physiological role of 
each receptor.   
Since no direct studies have determined how ligands bind to 5-HT2 
receptors,[9] we will use computational methods to predict the 3D structure of the 
receptors and of the ligand-receptor complexes.  Since there are no experimental 
structures for comparison, we validate our predicted structures indirectly by 
comparison with available mutagenesis and ligand binding experiments. Then we 
predict the results for new mutation and binding studies that could be carried out 
experimentally.  We report here the results for 5-HT2C, and preliminary results for 
5-HT2B.  These studies should provide the data needed to design sub-type 
specific drugs and to determine the origin of physiological responses to different 
agonists and antagonists. 
The 5-HT2C receptors are found in many regions of the brain.  Some 
evidence suggests that 5-HT2C may play a role in the mediation of the sleep-
wake cycle.[10] The activation of 5-HT2C appears also to be correlated with penile 
erections.[10] Several studies have suggested a prominent role for 5-HT2C 
receptors in the regulation of food intake and energy balance, and that 5-HT2C 
agonists act as appetite suppressants.[11] Additionally, 5-HT2C is believed to be 
involved in anxiety, feeding behaviors, and anxiety-related disorders like 
obsessive compulsive disorder (OCD).[11] In fact, 5-HT2C agonists can intensify 
the symptoms of schizophrenia and OCD.  However, it is difficult to determine 
whether these symptoms are caused solely by 5-HT2C activation because the 
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activation of other 5-HT receptors, most notably 5-HT2A, is implicated in similar 
physiological effects.[11] 
In order to provide the basis for designing subtype specific agonists and 
antagonists for the 5-HT2C receptor, we set out to obtain the 3D structure of this 
receptor and for ligands binding to it.  We did not use homology modeling 
because of the two experimentally known 3D structure for GPCRs, 5-HT2C is only 
19% homologous to bovine rhodopsin[3] and 31% homologous to the beta(2)-
adrenergic receptor, whose structure has been recently solved.[5] Additionally, we 
have found in studies of other GPCRs that systems with even 80% sequence 
identity can have different binding sites.  Instead, we used the MembStruk GPCR 
structure prediction procedure to predict the 3D structure.  MembStruk has been 
used successfully to predict the structures for CCR1 chemokine receptor, 
MrgC11 tetrapeptide receptor and DP prostanoid receptor, in each case for 
which experimental validation was done after the predictions.  In addition, 
predictions of the structures for D2 dopamine receptor, β2 adrenergic receptor 
and M1 muscarinic acetylcholine receptor are in good agreement with numerous 
mutation and ligand binding experiments.  Furthermore, predictions of olfactory 
receptors, the PTC bitter-taste receptor, and rhodopsin agree with somewhat 
more limited ligand binding experiments.[2, 7, 12-18] 
Here we report the structure prediction for the 5-HT2C receptor, and then we 
use the MSCDock procedure[19] to predict the binding sites of serotonin and three 
strongly binding antagonists.  In addition, we predict the binding of ten psilocybin 
analogs to compare with experimental SAR data.  We also compare the 
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predicted structure for 5-HT2C with a preliminary prediction of 5-HT2B.  In all 
cases, we obtain excellent agreement with currently available data and we 
predict new experiments to validate further the predicted structures. 
 
Methodology 
We used the MembStruk procedure (version 4.30)[2, 7] to predict the structure of 
the 5-HT2C receptor.  This procedure consists of five main steps: 
1. Prediction of the transmembrane (TM) helices from hydrophobic analyses 
of the amino acid sequence. 
2. Assembly of the seven-helix TM bundle and coarse grain optimization of 
the bundle. 
3. Rigid body dynamics of the bundle in an explicit lipid bilayer. 
4. Optimization of individual helices. 
5. Optimization of the entire protein.  
Throughout these steps, MPSim[20] was used with the Dreiding forcefield[21] for 
the molecular mechanics and molecular dynamics steps unless otherwise 
specified, with a dielectric constant of 2.5, and a 6-12 Lennard-Jones potential for 
the van der Waals interactions. 
TM Predictions   
The prediction of the TM helical regions is based on the assumption that the 
outward facing sections of the TM helices must be hydrophobic because they are 
in contact with the hydrocarbon tails of the lipid bilayer, and that the hydrophobic 
center of each helix should be at the center of the membrane.[22] These ideas are 
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used in the TM2ndS program to determine the TM helical regions with a 
hydrophobic profile and helical capping rules.  To determine the hydrophobic 
profile, sequences related to 5-HT2C were found with NCBI BLAST.[23] Of the 
~200 sequences, we selected an ensemble of ~100 sequences having a uniform 
distribution of sequence identities from 20% to <100%.  These sequences 
(including the target) were aligned with ClustalW to generate pairwise multiple 
sequence alignments.[24] From the multiple sequence alignments, we kept only 
the 40 sequences for mouse, rat and human receptors. 
We used the Eisenberg hydrophobicity scale[25] (which assigns each amino 
acid a hydrophobicity value ranging from −1.76 to 0.73) to estimate the 
hydrophobicity for each residue position in the alignment, and we averaged this 
over all of the sequences in the multiple sequence alignment.  The Eisenberg 
scale was used because we validated our TM predictions on bovine rhodopsin 
using this hydrophobicity scale.[2] Then, we calculated the hydrophobic profile by 
averaging the hydrophobicity over a range of window sizes ranging from 12 to 20, 
and selected the lowest window size that gives seven peaks with lengths greater 
than 20 residues.  The baseline value is the average hydrophobicity over all of 
the amino acids in the protein, which for 5-HT2C is 0.007.  Because the TM 
helices can extend past the membrane surface, we use capping rules to refine 
the helix predictions.  Known helix breakers are proline, glycine, arginine, 
histidine, lysine, aspartic acid and glutamic acid.  If any such helix breakers are 
found within four residues toward the membrane, we keep the initial TM helix 
predictions.  If no helix breaker is found, the helix is extended until a breaker is 
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found, but only up to six residues. Additionally, the capping rules include the 
requirement that the intracellular and extracellular loops consist of at least six 
residues.  Then we define the hydrophobic center of each TM helix as the point 
of maximum hydrophobicity averaged over the range of window sizes.  The 
hydrophobic profile for 5-HT2C is shown in Figure 1.  
 
 
Figure 1. The hydrophobic profiles for the multiple sequence alignment of the 5-
HT2C based on aligning the entire sequence.  The bold line is the baseline 
hydrophobicity value.  
 
 The edges of some of the TM helices were not well defined, without any 
residues left to form a loop between TM2 and TM3.  Thus, to further refine the 
predictions, each individual TM helix was BLAST searched separately.  For each 
helix, we consider the ten residues on either side of the hydrophobic center and 
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make a new BLAST over the GPCR database to obtain a new set of sequences 
(>20% identity) and then we did a new alignment with these sequences as input 
to the TM2ndS program.  Next, the peak for the specific helix was examined, 
along with capping rules, to determine the edges of the helix.  The hydrophobic 
centers calculated with the entire protein sequence in the previous step were 
retained.  The predictions, before and after individual helical refinement and 
helical capping, are given in Table 1.  Table 1 shows that the final TM predictions 
were taken to be the capped individual helix predictions, except for the case of 
TM5.  Here, the capping procedure added six residues to TM5, which we 
considered to make the helix too long, especially in comparison to TM5 of 5-HT2B.  
Thus, we adjusted the prediction for TM5 to end at a tyrosine. 
Packing of the TM Helices into a Seven-Helix Bundle  
The seven TM helices predicted by TM2ndS were next built in to a TM bundle.  
First, we built each TM helix into a canonical right-handed alpha-helix with 
extended side chain conformations.  Then we placed each so that all seven have 
their calculated hydrophobic centers in an imaginary plane running through the 
center of the lipid bilayer. 
We orient the most hydrophobic face of each helix to point away from the 
center of the bundle (based on equal weight for each center) because we expect 
that it will be energetically favorable for the most hydrophobic part of each helix 
to be facing outward toward the hydrophobic lipid bilayer.  This is achieved by 
calculating the hydrophobic moment of each helix, considering the fifteen 
residues on either side of the hydrophobic center, but including just the face of 
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the helix (considering 180o of the projection on a plane perpendicular to the 
helical axis).  The hydrophobic moment is pointed outward from the center of 
mass of the protein. 
 
Table 1. TM helix predictions for 5-HT2C 
TM  Predicted TM Region Prediction Method 
1  GVQNWPALSIVIIIIMTIGGNILVIMA 
 GVQNWPALSIVIIIIMTIGGNILVIMAVSME 
 GVQNWPALSIVIIIIMTIGGNILVIMA 
 GVQNWPALSIVIIIIMTIGGNILVIMAVSME 
 GVQNWPALSIVIIIIMTIGGNILVIMAVSME    
Full protein, uncapped 
Full protein, capped 
Indiv. helix, uncapped 
Indiv. helix, capped 
Final Prediction 
 2       YFLMSLAIADMLVGLLVMPLSLLAILYD--Y 
   ATNYFLMSLAIADMLVGLLVMPLSLLAILYD-- 
     NYFLMSLAIADMLVGLLVMPLSLLAILYDY 
    TNYFLMSLAIADMLVGLLVMPLSLLAILYD 
    TNYFLMSLAIADMLVGLLVMPLSLLAILYD 
Full protein, uncapped 
Full protein, capped 
Indiv. helix, uncapped 
Indiv. helix, capped 
Final Prediction 
 3  PRYLCPVWISLDVLFSTASIMHLCAISLDR 
  RYLCPVWISLDVLFSTASIMHLCAISLDR 
 PRYLCPVWISLDVLFSTASIMHLCAISLDR 
  RYLCPVWISLDVLFSTASIMHLCAISLDR 
  RYLCPVWISLDVLFSTASIMHLCAISLDR 
Full protein, uncapped 
Full protein, capped 
Indiv. helix, uncapped 
Indiv. helix, capped 
Final Prediction 
 4         MKIAIVWAISIGVSVPIPVIG 
       IMKIAIVWAISIGVSVPIPVIGL  
       IMKIAIVWAISIGVSVPIPVIG 
      AIMKIAIVWAISIGVSVPIPVIGL 
      AIMKIAIVWAISIGVSVPIPVIGL 
Full protein, uncapped 
Full protein, capped 
Indiv. helix, uncapped 
Indiv. helix, capped 
Final Prediction 
 5       FVLIGSFVAFFIPLTIMVITYCL 
      FVLIGSFVAFFIPLTIMVITYCLTIYVLR 
      FVLIGSFVAFFIPLTIMVITYCL 
      FVLIGSFVAFFIPLTIMVITYCLTIYVLR 
      FVLIGSFVAFFIPLTIMVITYCLTIY 
Full protein, uncapped 
Full protein, capped 
Indiv. helix, uncapped 
Indiv. helix, capped 
Final Prediction 
 6        LGIVFFVFLIMWCPFFITNILSVLC 
       LGIVFFVFLIMWCPFFITNILSVLCE 
       LGIVFFVFLIMWCPFFITNILSV 
       LGIVFFVFLIMWCPFFITNILSVLCE 
       LGIVFFVFLIMWCPFFITNILSVLCE 
Full protein, uncapped 
Full protein, capped 
Indiv. helix, uncapped 
Indiv. helix, capped 
Final Prediction 
 7     EKLLNVFVWIGYVCSGINPLVYT 
    EKLLNVFVWIGYVCSGINPLVYT 
    EKLLNVFVWIGYVCSGINPLVYT 
    EKLLNVFVWIGYVCSGINPLVYT 
    EKLLNVFVWIGYVCSGINPLVYT 
Full protein, uncapped 
Full protein, capped 
Indiv. helix, uncapped 
Indiv. helix, capped 
Final Prediction 
 
 
The predictions are given for both the initial predictions based on the full protein 
sequence and for the subsequent prediction in which each TM regions was 
searched and aligned individually.  In each case, the predictions are based on 
hydrophobicity and supplemented with predictions based on capping rules.  A 
gap (-) in a sequence is caused by the multiple sequence alignment.  In the final 
predictions, the calculated hydrophobic center for each helix is indicated by a 
boxed residue. 
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The calculation of the center fixes the z coordinate for each helix, while the 
rotational orientation determines the η angle. There remain four other parameters 
to uniquely position each helix: the x and y position in the plane through the 
center of the lipid, the tilt θ of the helix from the z-axis perpendicular to the plane, 
and the azimuthal angle φ for the tilting plane. These four parameters we take 
from the 7.5 Å electron density map of frog rhodopsin.[26] This electron density 
map gives the relative orientations of the helical axes, but no information about 
translation or rotation of the helices.  The original MembStruk was developed 
using frog rhodopsin because there was no bovine rhodopsin x-ray available at 
that time.  We found that frog rhodopsin worked well and saw no need to change.  
Only the overall x and y position and tilt (θ, φ) are used from the template.  No 
detailed atom information is used.  Thus we use only undifferentiated electron 
density information from experiment.  We can take these parameters from any 
crystal structure or from the structure of a predicted GPCR structure after explicit 
lipid bilayer dynamics. 
 The six parameters x, y, z, θ, φ, and η for each helix uniquely determine how 
to pack the seven helices into the bundle. Next, we need to determine the 
structure within each helix.  First, we used SCRWL[27] to place each side chain 
appropriate for the seven-helix bundle.  Then, we inserted counterions to offset 
the charged residues not in salt bridges.   
Rigid Body Dynamics of the Bundle in an Explicit Lipid Bilayer   
In order to allow the helices to deviate from ideal alpha-helix structure, as is 
experimentally observed in transmembrane helices, we carried out torsional 
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molecular dynamics (NEIMO MD)[28] for each individual helix at 300 K for 500 ps.  
The helices with prolines form bends due to the disruption of the alpha-helix 
hydrogen bonding network.  The lowest energy structure from the last 250 ps 
was chosen and minimized (using conjugate gradients).  Then, all seven 
minimized helices were bundled together again by CRMS matching the 
structures back on to the original positions.  The side chains were then 
reassigned using SCRWL, and the entire bundle was minimized.  Finally, the 
helices were again optimized rotationally and translationally as described in the 
previous step. 
Optimization of Individual Helices within the Bundle  
Although the hydrophobic nature of the hydrocarbon tails in the membrane are 
important in determining the rotational orientation of the helices, interhelical 
hydrogen bonds and salt bridges also help stabilize the structure.  Residues 
conserved across all biogenic amine receptors are expected to be involved in 
these hydrogen bonding interactions, playing a role in stabilization, binding, 
and/or activation.  Accordingly, it is likely that they will be facing in toward the 
bundle in order to interact with the ligand or other helices.  Moreover, TM3 is 
near the center of the helical bundle, and hence it is less affected by the 
membrane environment than the other helices.  Consequently, orientation by 
hydrophobic moment is less appropriate for TM3.  Thus, we carried out 
subsequent optimization of the rotational orientation of the helices by using 
energy minimization techniques. 
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Starting with the phobic face orientation, we use energy minimization to 
optimize the rotation of each helix.  Here, each helix is rotated and optimized 
through a range of angles.  For each angle, the helices are rotated in the order 3 
2 1 7 6 5 4, starting with the inner TM3 for which the phobic face orientation is 
least likely to be optimum (because it interacts least with the hydrophobic 
membrane).  The procedure is as follows: The first helix is rotated 5o and −5o, 
and for these angles, the side chain positions of all seven helices are reassigned 
using SCRWL and the energy of the active helix is minimized (conjugate 
gradients) in the field of all of the other helices (whose atoms are kept fixed).  
The lowest energy conformation for the helix at 0o, 5o or −5o is chosen, and the 
helix fixed at this angle.  Then, in succession, each of the other six helices is put 
through the same ±5o rotation procedure with the other helices fixed.  After all 
seven helices have been rotated ±5o and fixed in their lowest energy 
conformation, the same procedure is repeated for increments of ±10o.  This 
process is repeated with 5o increments up to ±25o.  Then the process is 
continued with the angles decreased by 5o increments back down to ±5o, where 
at each level all helices are allowed to adjust to the environment of the other 
helices.  The net rotations accomplished by this process for TMs 1 through 7 are 
0o, 5o, −10o, 5o, 55o, 0o, and 10o. 
After selecting this lowest energy rotation, the entire helical bundle is energy 
minimized. 
The helical bundle attained by energy-based rotation in the previous step is 
next immersed in a lipid bilayer made up of 52 explicit DLPC molecules in two 
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layers around the bundle.  The protein is first energy minimized in this bundle, 
then we carry out 50 ps of rigid-body dynamics at 300 K are (using MPSim).[20] In 
this calculation, the helices and lipid bilayer molecules are treated as rigid bodies.  
This dynamics step helps to optimize the vertical helical translations and 
rotations in an explicit lipid bilayer and to optimize the positions of the lipid 
molecules with respect to the helical bundle. After this simulation, we used 
SCRWL to replace the side chains, now using the lipid molecules as a bump test. 
Next, we again considered helical rotations, but this time each helix was 
rotated a full 360o, in increments of 5o, with the other six helices fixed during the 
entire range of rotations.  For each angle, we used SCRWL to reassign side 
chains, and then energy minimized all atoms of the seven helices and the explicit 
lipid bilayer.   
For each rotated angle of a helix, the energy of the helix interacting with the 
six other helices is tabulated, along with the number of interhelical hydrogen 
bonds and the hydrophobic penalty.  The hydrophobic penalty is calculated in 
order to ensure that it is not favorable for polar and charged residues to point into 
the lipid bilayer.  With the lipids ignored, we consider that any residue with more 
than 60% of its surface area accessible to a solvent probe of radius 2.0 Å is 
pointing outward toward the lipid bilayer.  Then the percentage of solvent 
accessible surface for each residue pointing outward within seven amino acids of 
the hydrophobic center is multiplied by the hydrophobicity value of the amino acid.  
The hydrophobicity scale used is the average of the augmented Wimley White 
scale[29] and the White interface scale.[30] We use this hydrophobicity scale for the 
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hydrophobic penalty instead of the Eisenberg scale used to determine the TM 
regions because it is thermodynamically based, and we are performing energy 
calculations in this step. We are currently testing our TM prediction algorithm with 
this thermodynamically based hydrophobicity scale.  These calculated 
hydrophobic penalty values were used to determine which region of angles to 
choose for each of the six TMs (excluding TM3 which has little direct contact with 
the lipid bilayer). 
The specific residues involved in each interhelical hydrogen bond were 
identified so that hydrogen bonds involving residues conserved within class A 
and biogenic amine receptors could be given more importance in choosing 
angles for combinatorial analysis.  The residues focused on were  
• ASN71 in TM1, ASP99 in TM2, and TRP179 in TM4 (all highly conserved 
among class A GPCRs), and  
• ASP134 in the center of TM3, TRP324 in TM6, and ASN364 in TM7, 
(conserved among all mammalian biogenic amine receptors).[31]   
Experiments on various GPCRs suggest that the TM2 aspartic acid forms a 
hydrogen bonding network with the asparagines in TM1 and TM7.[32, 33] The TM3 
aspartic acid is known to bind the amino functional group in biogenic amines.[34] 
The TM4 tryptophan is the most highly conserved residue across the entire 
GPCR superfamily, and is thought to be integral in structural stabilization.[34] The 
TM6 tryptophan is believed to be important in activation.[34] TM5 is the least 
conserved helix in GPCRs, suggesting its role in ligand specificity.  A proline is 
highly conserved among class A GPCRs, but its role is most likely to disrupt the 
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hydrogen bonding within the helix and create flexibility.[34] Thus, it would not 
necessarily be pointing in to interact with other helices or the ligand. 
   The list of specific hydrogen bonds formed for each helical rotation is used 
to help choose angles for combinatorial analysis.   
• If a hydrogen bond occurs between two conserved residues, the angles 
for the two helices are retained.   
• If the hydrogen bond involves just one conserved residue, we choose the 
angle or angles that retain the hydrogen bond and have the best 
combination of energy, hydrogen bonding and hydrophobic penalty.   
• If a helix does not have a conserved residue involved in a hydrogen bond, 
the angle or angles with the best energy, number of hydrogen bonds and 
hydrophobic penalty are selected.   
The rotational profile for each TM is shown in Figure 2. Based on the selection 
criteria, we selected 0o for TM1; 175o and −125o for TM2; 0o, −20o and −45o for 
TM3; −50o and −75o for TM4; −35o and −75o for TM5; 90o for TM6; and 170o for 
TM7.  This leads to 24 cases, for each of which we used SCRWL to reassign 
side chains and then minimized the energy.  These structures were ranked by 
number of hydrogen bonds and then by energy as shown in Table 2.  The final 
rotations for TMs 1 through 7 were  
0o, −125o, −20o, −50o, −75o, 90o, and 170o. 
The lipid and counter ions were removed from the final structure and it was fully 
minimized.  The final structure is shown in Figure 3. 
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Figure 2. The hydrophobic penalty, energy, and number of hydrogen bonds for 
each rotation angle for each transmembrane helix.  For each property, values 
toward the outside of the graph are more favorable.  The arrows are the angles 
chosen for each TM, and the bold arrows are the angles from the final structure. 
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Table 2.  Combinatorial analysis 
 
H-bonds Energy (kcal/mol) TM Angles 
4 597 0 -125 -20 -50 -75 90 170 
4 604 0 -125 -20 -50 -35 90 170 
3 480 0  175    0 -50 -75 90 170 
3 487 0 -125 -45 -75 -35 90 170 
3 498 0 -125 -45 -50 -35 90 170 
3 512 0 -125 -20 -75 -35 90 170 
3 539 0 -125    0 -75 -75 90 170 
3 553 0  175 -45 -50 -35 90 170 
3 553 0 -125    0 -50 -75 90 170 
3 564 0  175    0 -50 -35 90 170 
3 576 0 -125    0 -75 -35 90 170 
3 590 0 -125 -20 -75 -75 90 170 
3 594 0 -125    0 -50 -35 90 170 
3 930 0  175 -45 -75 -35 90 170 
2 498 0  175    0 -75 -35 90 170 
2 522 0  175 -45 -75 -75 90 170 
2 524 0 -125 -45 -50 -75 90 170 
2 527 0 -125 -45 -75 -75 90 170 
2 569 0  175 -20 -50 -35 90 170 
2 578 0  175 -45 -50 -75 90 170 
2 581 0  175 -20 -75 -75 90 170 
2 599 0  175 -20 -50 -75 90 170 
2 599 0  175 -20 -75 -35 90 170 
1 477 0  175    0 -75 -75 90 170 
 
Calculated energy and number of hydrogen bonds for the combinatorial set of 
TM angles chosen from the rotational analysis.  The structures are ordered by 
hydrogen bonds and then by energy.  
 
 
 
Figure 3. The final predicted structure of apo-5-HT2C.  Indicated explicitly are the 
six amino acids expected to be involved in important interhelical or ligand binding 
interactions. 
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Prediction of Ligand Binding Sites  
Given the final minimized structure for the apo-protein of 5-HT2C, we then docked 
various known ligands into the receptor: 
• serotonin, the endogenous ligand, an agonist; 
• three strongly binding antagonists: ritanserin, metergoline and 
methiothepin; and 
• a series of ten analogs of psilocybin, both agonists and antagonists. 
These ligands are shown in Figure 4.  
  
 
Figure 4. The structures and experimental binding constants to 5-HT2C for 
serotonin, three strongly binding antagonists, and a set of psilocybin analogs 
(derivatives 3 to 16).  The role of the receptor (whether it is an agonist or 
antagonist) is given if it has been determined experimentally. 
 22 
 The ligands were built and minimized (Cerius2) using the Dreiding force field 
with Mulliken charges from quantum mechanics (B3LYP flavor of DFT using the 
6-31G** basis set, calculated with Jaguar).  We also calculated the pKa values 
for each ligand using the pKa module of Jaguar to determine if the ligand would 
be charged, and which atom would become protonated at biological pH 7.4.  
These pKa values are listed in Table 5.  The docking was done with flexible 
ligands and a rigid protein. 
To search for the best binding site for each ligand, we first alanized the bulky 
nonpolar residues (leucine, isoleucine, valine, phenylalanine, tryptophan and 
tyrosine).  That is, each was mutated to alanine.  Then we used the negative of 
the molecular surface of the alanized protein to define the regions in which to 
sample different ligand conformation.  These void regions were mapped with a 
set of spheres.  Then, we defined 36 boxes, each a cube with 10 Å sides, grown 
from the center of mass of the spheres and covering the entire receptor.  Each 
ligand was docked (using Dock 4.0) into all 36 boxes and ranked by interaction 
energy and buried surface.  Then, we examined the boxes with a combination of 
the strongest bonding and buried surface, and selected boxes with a continuous 
range of spheres for subsequent docking with MSCDock.  As an example, the 
sphere set that the antagonists were docked into is shown in Figure 5. 
We then used MSCDock to dock each ligand into the selected boxes using 
the dock with diversity method.  This method uses Monte Carlo search 
techniques to find sites that pass bump tests and groups these into families for 
which all family heads are at least 0.6 Å CRMS different from the others. This is 
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carried out until the number of families is saturated.  Then we select the 50 
families with the best combination of energy and buried surface and continue 
generating docking configurations until there is an average of six children in each 
family. Then we calculated the energy for each child of each of these families, 
and associate the energy with the family head.  
 
 
Figure 5. The boxes containing the spheres into which the antagonists ritanserin, 
methiothepin and metergoline were docked.  All of the bulky, nonpolar residues 
have been alanized. 
 
Next for each of these 50 ligand configurations, we dealanize the bulky 
nonpolar residues back to their original form and reassign all side chains within 5 
Å of the ligand with SCREAM.  We minimize (conjugate gradients to 0.2 
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kcal/molÅ RMS force) the ligand and residues within 5 Å of the ligand with the 
rest of the protein fixed.  Then we minimize the entire complex to 0.2 kcal/molÅ 
RMS force.   
The top ten structures by total energy of the ligand-protein complex were 
selected as the best docked structures.  From these top ten structures, we 
selected the one with the best contacts between the functional groups of the 
ligand and the residues in the binding site.  Then we used SCREAM to reassign 
the side chains for the residues interacting most favorably with the functional 
groups of the ligand to obtain their optimal orientation with respect to the ligand.  
The ligand and residues within 5 Å were put through one quench-anneal cycle 
(50 K to 600 K and back over 11.5 ps), selecting the structure with the lowest 
potential energy structure.  This was followed by minimizing the energy of the 
entire ligand-protein complex.   
Serotonin, ritanserin, metergoline and methiothepin were all docked following 
this procedure.  For the 10 SAR ligands, we chose derivative 3 as the template 
and docked it using the above procedure.  Then, we generated a sphere set 
fitted to a region within 0.8 Å radius around the best docked derivative 3 
molecule.  Then the entire docking procedure was carried out over this smaller 
region for the other nine SAR ligands, keeping the bulky residues in place (not 
mutated to alanine). 
Molecular Dynamics Simulation   
A simulation was performed on serotonin bound in 5-HT2C in order to determine 
the stability of the predicted bound structure.  NAMD 2.5[35] was used to perform 
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5 ns of full solvated lipid bilayer simulation.  First, loops were added with a Monte 
Carlo loop builder.  Only the first and last ten residues of the ic3 loop were added.  
The loops were built so that the disulfide bridge between the two cysteines in ec2 
and the top of TM3 was preserved.  Ten residues each of the N-terminus and C-
terminus were added.  Then, the helices and side chains were frozen while loops 
were put through a quench-anneal cycle.  Next, palmitoyloleoyl-
phosphatidylethanolamine (POPE) lipid molecules were added, along with a 
layer of water above and below.  Chloride ions were added to neutralize the 
charge of the system.  The membrane and water molecules were minimized with 
the protein fixed, and then equilibrated for 500 ps in an NPT simulation.   Then 
the loops were minimized along with the membrane and water molecules, and 
equilibrated for 500 ps in an NPT simulation.  Finally, the entire system was 
minimized, and then 5 ns of NPT simulation was run.  All NPT simulations were 
run using Langevin dynamics with a damping coefficient of 1 ps-1 and a bath 
temperature of 310 K.  The pressure was kept constant by Nosé-Hoover 
Langevin piston pressure control, with a target pressure of 1 atm and barostat 
oscillation and damping times of 200 fs.  The stepsize was 1 fs, with periodic 
boundary conditions applied.  Particle mesh Ewald was used for electrostatic 
calculations, with a nonbond cutoff of 12.0 Å and the nonbonded interactions of 
all 1-3 pairs included.  The energy and volume of the system equilibrated quickly, 
as shown in Figure 6. 
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Total energy of serotonin bound in 5-HT2C in a solvated lipid bilayer
-30000
-29500
-29000
-28500
-28000
-27500
-27000
0 500 1000 1500 2000 2500 3000 3500 4000 4500 5000
Time  (ps)
Energy 
(kcal/mol)
 
Total volume of serotonin bound in 5-HT2C in a solvated lipid bilayer
340000
341000
342000
343000
344000
345000
346000
347000
348000
349000
350000
0 500 1000 1500 2000 2500 3000 3500 4000 4500 5000
Time  (ps)
Volume 
(cubic Ang)
 
Figure 6. The energy and volume of serotonin bound in 5-HT2C in a solvated lipid 
bilayer during the 5 ns simulation. 
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Binding Energy Calculations 
For all the docked structures, the binding energies were calculated as  
Ebind = Ecomp,vac – Eprot,vac – Elig,vac – Elig,solv. 
Since the binding energy is the change in energy upon binding, more negative 
binding energies indicate stronger binding.  The energies of the separate protein 
and ligand were not reminimized.  That is, they were taken directly from the 
bound complex (to obtain the snap binding energy).  This assumes that there is 
little change in energy of the separated ligand and protein upon minimization.  
This also does not take the solvation of the complex or the protein into 
consideration.  However, for small molecules binding in the core of the protein 
like those we are working with, the solvation energy of the bound complex should 
not differ greatly from that of the unbound protein.  The solvation energy of the 
ligand was calculated using the Poisson-Boltzmann continuum solvent 
approximation (dielectric constant of 80 and solvent radius of 1.4 Å) using the 
Delphi program.  The vacuum energies were calculated with MPSim, as in all of 
the structure prediction steps, so the solute dielectric was 2.5.  
Next, we neutralized all charged residues of the system and the ligand by 
transferring the hydrogen of each salt bridge from the acceptor back to the donor 
and by adding a proton to each exposed Asp or Glu and removing one from each 
Lys and Arg.  We used a modified Dreiding forcefield that included special 
hydrogen bonding parameters chosen to reproduce the binding for dimers of 
analogous residues found from QM.  Each full ligand-protein complex was then 
reminimized and the binding energies for the neutral forcefield were calculated 
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according to the same equation as for the charged case, but with the addition of 
a pKa penalty term.  This is the energy change required to neutralize the ligand 
or residue that prefers to be charged in water solvent.  For a positively charged 
ligand this is equal to 1.4 * (pKa − 7.4) kcal/mol. 
This modified neutral Dreiding forcefield was also used to calculate the 
contributions of individual residues to binding.  As in all of the other Dreiding 
calculations, the dielectric constant was 2.5, with van der Waals interactions 
calculated by a 6-12 Lennard-Jones potential.  The nonbond interactions were 
calculated between the bound ligand and all residues within 5 Å of the ligand. 
 The neutral residue scheme is an improvement over the charged residue 
scheme for the binding energy calculations because it decreases the large 
variations between complexes caused by exaggerated long-range Coulombic 
interactions between charged groups.  These exaggerated interactions are due 
to the fact that the charges are fixed in molecular mechanics, so charge 
screening is not present to damp the long-range interactions.  Additionally, in the 
hydrophobic membrane environment, many of the residues may already be 
neutral.  The neutralization procedure is carried out for the binding energy 
calculations and not the docking procedure because the large Coulombic 
interactions are important to ensure that binding modes with a salt bridge are 
selected. 
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Results and Discussion 
Serotonin Binding 
Serotonin is the endogenous agonist to 5-HT2C with a binding constant of Ki = 
16.0 nM.[36] The predicted binding site for serotonin to our predicted structure for 
5-HT2C is shown in Figure 7 and the cavity analysis is in Table 3.  The most 
important contacts are 
• D134(3) forms a salt bridge with the protonated primary amine site       
(8.7 kcal/mol), which makes excellent sense.  Indeed, experiments 
suggest that D134(3) creates a salt bridge with the protonated nitrogen of 
biogenic amines.[34] 
• The protonated primary amine also forms a hydrogen bond with S138(3) 
(5.7 kcal/mol). 
• The aromatic indole group has very good van der Waals interactions with 
F223(5) (3.0 kcal/mol) and F328(6) (4.9 kcal/mol).  The ring is stacked 
between the two phenylalanines. 
• The polar NH of the indole forms a hydrogen bond with S219(5)            
(6.5 kcal/mol). 
• The OH substituent of the indole forms hydrogen bonds both with S141(3) 
(3.3 kcal/mol) and W324(6) (2.0 kcal/mol). 
• There is good van der Waals interaction between the indole and I332(6) 
(2.0 kcal/mol). 
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Figure 7. The predicted structure (side and top views) of serotonin bound to 5-
HT2C.  TMs 1, 2, 4 and 7 are not shown since they do not interact directly with the 
ligand.  The residues shown are those within 5.0 Å of serotonin that have more 
than 2 kcal of favorable interaction with the ligand.  The dotted lines indicate 
hydrogen bonds with serotonin.  
 
 
 
Table 3. Nonbond interaction energies (kcal/mol) between each ligand and 
individual residues within 5.0 Å of the ligand 
 
 D134 F328 S219 F223 S138 I332 W324 V215 P190 S141 
TM helix no. 3 6 5 5 3 6 6 5 4 3 
Ritanserin -9.6 -0.4 -1.5 -1.6 -0.3 -4.1 -8.5 -3.2 -1.9 0.3 
Metergoline -10.9 -0.5 -1.8 -0.9 -7.4 -1.6 -0.2 -5.9 -4.7 -0.2 
Methiothepin -12.2 -1.5 -6.1 -1.8 -1.3 -0.8 -0.3 -2.3 -3.9 0.0 
Deriv 5 -9.8 -6.9 -4.9 -4.3 -2.7 -2.9 -2.4 -0.5 -0.2 0.4 
Deriv 3 -9.0 -6.1 -4.8 -6.3 -2.4 -2.3 -1.4 -0.7 -0.2 -1.0 
Serotonin -8.7 -4.9 -6.5 -3.0 -5.7 -2.1 -2.0 -0.3 -0.1 -3.3 
Deriv 13 -9.0 -6.6 -5.0 -3.2 -1.2 -1.7 -1.9 -0.3 -0.1 -0.8 
Deriv 9 -9.0 -5.9 -1.3 -4.8 -2.1 -3.1 -1.7 -0.3 -0.1 -0.2 
Deriv 14 -8.4 -6.4 -4.1 -5.5 -1.3 -1.2 -1.0 -0.5 -0.1 -0.2 
Deriv 16 -11.2 -4.8 -4.6 -5.8 -1.2 -2.7 -0.9 -0.6 -0.1 -0.1 
Deriv 12 -12.3 -6.1 -5.3 -3.2 -1.5 -3.2 -1.8 -1.6 -0.9 -0.7 
Deriv 11 -2.7 -6.1 -5.1 -4.8 -1.6 -1.7 -1.7 -2.8 -1.6 -0.6 
Deriv 15 -9.5 -4.4 -0.8 -4.0 -1.8 -2.0 -2.2 -0.1 -0.1 -6.1 
Deriv 7 -8.2 -6.3 -1.9 -4.2 -1.6 -2.7 -1.4 -0.7 -0.2 -0.2 
Average -9.3 -4.8 -3.8 -3.8 -2.3 -2.3 -2.0 -1.4 -1.0 -0.9 
 
Here we list only the residues that have more than 2 kcal of favorable energy 
with at least two ligands.  The ligands are ordered by decreasing experimental 
binding strength (see Table 5). 
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Overall, the bound structure for serotonin looks reasonable, with each polar 
functional group of serotonin making favorable interactions with a polar or 
charged residue in the binding pocket and with excellent aromatic interactions.   
Bound Serotonin Dynamics   
In order to determine the stability of this bound structure, we carried out a 5 ns 
simulation of this complex in an explicit lipid bilayer.  This simulation shows the 
predicted structure and binding site to be stable for 5 ns. The structure after 5 ns 
is shown in Figure 8.  Some of the hydrogen bond contacts made with serotonin 
do change throughout the simulation, but the ligand stays in the same binding 
site, just moving a little downward toward the intracellular region.  The hydrogen 
bond with S219(5) and the van der Waals interactions with I332(6) are lost as 
serotonin moves downward.  The hydrogen bond with S141(3) is lost as the 
oxygen of the OH substituent of serotonin forms a very strong hydrogen bond 
with W324 and the hydrogen of the OH group forms a hydrogen bond with the 
backbone oxygen of S138(3).  Both D134(3) and S138(3) maintain their strong 
hydrogen bonds with the protonated amine group of serotonin.  Additionally, both 
F223(5) and F328(6) preserve their strong van der Waals interactions with the 
indole serotonin throughout the simulation.  The distances between serotonin 
and key residues during the simulation are shown in Figure 9.  Waters enter the 
binding site and accumulate around the salt bridge between D134(3) and 
serotonin.  There were no additional restraints placed on the helices to prevent 
them from unraveling, so the C-terminus of TM1 unraveled by two residues, the 
N-terminus of TM2 by one residue, the N-terminus of TM3 by one residue, and 
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the N-terminus of TM7 by one residue.  The TMs 1-2-7 hydrogen bonding 
network is retained, although the helices do translate with respect to each other 
during dynamics.  
 
 
Figure 8. Serotonin bound in 5-HT2C after 5 ns of dynamics.  The top shows the 
TMs 1-2-7 hydrogen bonding network, as well as the disulfide bond between the 
two cysteines in TM3 and ec2.  The water molecules shown are those within 5.0 
Å of serotonin.  The bottom shows the binding pocket, with the important 
residues from the structure before minimization or dynamics.  The dotted lines 
indicate hydrogen bonds with serotonin.   
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Figure 9. The calculated distances between serotonin and residues predicted to 
be important in binding at 50 evenly spaced snapshots of the 5 ns simulation. 
 
 
Comparison to Mutagenesis Experiments   
Since no experimentally determined structures for any serotonin receptors are 
available, experimental validation must come from additional mutagenesis 
studies, in which residues in the active site are mutated to various amino acids 
and the effect on ligand binding determined.  Many experimental studies have 
been performed on 5-HT2 receptors, with the majority of the mutation 
experiments focused on 5-HT2A.  Although there are differences between the 
receptors, we find 70% sequence identity and 88% sequence similarity between 
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5-HT2A and 5-HT2C in the predicted TM regions, so it can be useful to compare 
our predicted structure with experimental findings on 5-HT2C.  
• D155(3) in 5-HT2A, which corresponds to D134(3) in 5-HT2C was found to 
anchor the terminal amine moiety of serotonin,[37] as we predict in 5-HT2C.   
• An alanine substitution of S159(3) in 5-HT2A, corresponding to S138(3) in 
5-HT2C, was found to decrease serotonin binding by 18-fold,[38] leading to 
the proposal that S159(3) forms a hydrogen bond with the protonated 
amine group of serotonin, just as we predict for 5-HT2C. 
• S239(5) in 5-HT2A, which is an alanine in 5-HT2C that is one turn away 
from S219(5), is proposed to form a hydrogen bond to the polar NH of the 
indole in serotonin.[39] We predict that in 5-HT2C, the NH of the indole in 
serotonin forms a hydrogen bond with S219(5), but we find this hydrogen 
bond to disappear after 5 ns of dynamics.   
• F243(5) and F244(5) in 5-HT2A are found to have significant interactions 
with serotonin, with both predicted to point in toward the binding pocket.[40] 
F243(5) in 5-HT2A corresponds to F223(5) in 5-HT2C, which we predict to 
have very good van der Waals interactions with serotonin, but we predict 
F224(5) not to interact strongly with serotonin in 5-HT2C.   
• Mutation of F340(6) to leucine in 5-HT2C significantly decreases serotonin 
binding, but mutation of F339(6) to leucine did not affect binding.[41] We 
predict the same effect in 5-HT2C with serotonin making very good van der 
Waals interactions with F328(6), but not significantly interacting with 
F327(6).   
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• Mutation of W336(6) to alanine was found to cause an almost 1000-fold 
decrease in serotonin binding in 5-HT2A.[42] We predict the corresponding 
residue in 5-HT2C, W324(6), to have good van der Waals and hydrogen 
bonding interactions with serotonin. 
Our predicted serotonin binding site for 5-HT2C has many similarities to 
experimentally determined features of the 5-HT2A binding site.  A homology 
model of 5-HT2C based on the crystal structure of bovine rhodopsin[3], produced 
by the WHAT IF program[43] does not agree with these mutagenesis experiments 
as well as our predicted structure.  TM5 has S219(5) pointed away from the 
binding pocket, towards TM6.  Additionally, D134(3) is pointed towards the 1-2-3-
7 pocket instead of the 3-5-6-7 pocket.  Thus, serotonin would not bind in the 3-
5-6-7 pocket, as expected for biogenic amine receptors.[44] 
The recently determined experimental structure of the beta(2)-adrenergic 
receptor[5] has more similarities to our predicted structure for 5-HT2C than does 
the structure of bovine rhodopsin, but there are still some key differences in the 
predicted binding site.  The TM5 serine in the beta2 structure that corresponds to 
S219(5) in 5-HT2C is pointing in toward TM3.  However, the well conserved TM3 
aspartic acid in beta2 thought to anchor the protonated amine of bound biogenic 
amines is pointing towards the 1-2-3-7 pocket, as seen in bovine rhodopsin.  
Thus, in a homology model of 5-HT2C based on the crystal structure of the 
beta(2)-adrenergic receptor, serotonin cannot make good contacts with both 
D134(3) and S219(5) as we predict in our structure. 
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Based on our predicted bound structure and its dynamics, additional 
experiments that could help validate our predicted binding site are D134A, 
S138A, F328A, F223A and W324, all of which would lead to significant 
decreases in serotonin binding affinity.  Although the simulation shows the 
hydrogen bond between serotonin and S219(5) to be absent after 5 ns, it may 
reappear after a longer simulation, so S219A could also lead to a decrease in 
serotonin binding affinity. 
 
Ritanserin Antagonist Binding   
Ritanserin is an antagonist to 5-HT2C with a binding constant of Ki = 0.25 nM.[45]  
It is used for the treatment of many neurological disorders.  The predicted binding 
site for ritanserin to our predicted structure for to 5-HT2C is shown in Figure 10 
and the cavity analysis is in Table 3.  The most important contacts are as follows. 
• The protonated nitrogen of the piperidine forms a salt bridge with D134(3) 
(9.6 kcal/mol). 
• The oxygen of the pyrimidine makes a hydrogen bond with W324(6)     
(8.5 kcal/mol). 
• The aromatic thiazolo-pyrimidine group has strong van der Waals 
interactions with F137(3) (4.9 kcal) and N331(6) (2.2 kcal). 
• The flourophenyl groups have strong van der Waals interactions with 
I332(6) (4.1 kcal/mol) and V215(5) (3.5 kcal/mol). 
Note that the sulfur of the thaizole does not make strong interactions with polar or 
charged residues.  This suggests that improved binding might be obtained by 
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modifying I363(7) or V359(7) to polar residues able to hydrogen bond with the 
sulfur. Additionally, the fluorines of the antagonists do not interact strongly with 
polar or charged residues.  They may be interacting with the charged head 
groups of the lipid molecules, water molecules that enter the binding site, or 
charged or polar residues in the loops.   
Metergoline Antagonist Binding   
Metergoline is an antagonist to 5-HT2C with a binding constant of Ki = 0.29 nM.[36]  
Metergoline is used as an analgesic in migraine headaches.  The predicted 
binding site for metergoline to our predicted structure for to 5-HT2C is shown in 
Figure 10 and the cavity analysis is in Table 3.  The most important contacts are 
as follows. 
• D134(3) forms a salt bridge with the protonated nitrogen of the ergoline 
(10.9 kcal/mol). 
• Both the N-H group of the amide and the carboxyl oxygen of the ester 
makes hydrogen bonds with S138(3) (7.4 kcal/mol). 
• The aromatic ergoline group has strong van der Waals interactions with 
V215(5) (5.9 kcal/mol), P190(4) (4.7 kcal/mol), F214(5) (2.5 kcal/mol), and 
I189(4) (2.5 kcal/mol).  
• The phenyl group has good van der Waals interactions with I142(3)      
(2.9 kcal/mol) and I182(4) (2.0 kcal/mol). 
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Figure 10. Side and top views of ritanserin (top), methiothepin (middle) and 
metergoline (bottom) bound in 5-HT2C.  The TMs not shown do not directly 
interact with the ligand.  The residues shown are those within 5.0 Å of the ligand 
that have more than 2 kcal of favorable interaction with the ligand.  The hydrogen 
bonds formed between the protein and the ligand are indicated by dotted lines.   
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Methiothepin Antagonist Binding  
Methiothepin is an antagonist to 5-HT2C with a binding constant of Ki = 0.35 
nM.[45] It is used as an antipsychotic. (S)-methiothepin was docked for this study.  
The predicted binding site for methiothepin to our predicted structure for to 5-
HT2C is shown in Figure 10 and the cavity analysis is in Table 3.  The most 
important contacts are as follows. 
• D134 interacts with the protonated N at the center of methiothepin      
(12.2 kcal/mol).  
• The piperazine NH forms a hydrogen bond with S219(5) (6.1 kcal/mol). 
• The two benzene rings have good van der Waals interactions with 
P190(4) (-3.9 kcal/mol), W128(3) (2.8 kcal/mol) and V225(5) (2.3 kcal/mol).  
• I189(4) has good van der Waals interactions with the thiol ether            
(2.5 kcal/mol). 
Note that neither sulfur in methiothepin makes strong interactions with polar or 
charged residues.  This suggests that improved binding might be obtained by 
modifying I131(3), V135(3), G218(5) or I189(4) to polar residues able to form 
hydrogen bonds with the sulfurs.  If S186(4) was modified to an asparagine or a 
threonine, it may be long enough to form a hydrogen bond with the thiol ester 
sulfur. 
SAR for Psilocybin Analogs  
Since there is so little mutation data available for 5-HT2C, we will validate our 
predicted GPCR structure and binding sites by comparing calculated binding 
energies with experimental binding affinities.  Here we consider a series of 
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psilocybin analogs in which small structural changes were found to result in large 
changes in binding affinity.[46] The binding modes for the SAR ligands are shown 
in Figure 11.  The strength of interaction for each ligand with important residues 
in the binding cavities is given in Table 3.   
The binding site of the SAR ligands can explain most of the experimental 
binding data.  All of the ligands form a salt bridge with D134 except derivative 11, 
which pKa calculations show to be neutral in solution.  Derivatives 3, 5, 11, 12, 
13, 14 and 16 form strong hydrogen bonds between the hydroxyl group of the 
phenol and S219.  The position of the hydroxyl group in derivative 7 prevents any 
hydrogen bonding with S219, which in part leads to its bad binding.  The fluorine 
in derivative 9 that takes the place of the hydroxyl group does not hydrogen bond 
with S219, but still has favorable interactions with S219, so the binding to 5-HT2C 
is not as strong as for derivative 3 or 5, but is still fairly strong. In derivatives 13 
and 14, the carbon chain is shorter than in serotonin, but this ligand can still form 
hydrogen bonds with S219.  However, they do not bind as strongly as derivatives 
3 and 5, which have the same length carbon chain as serotonin.  A cavity 
analysis shows that there are decreased interactions with I332 and S138 in 
derivatives 13 and 14 compared to derivatives 3 and 5.  Derivative 16 also has 
decreased interaction with S138, caused by the extra methyl group branching 
from the carbon chain, causing part of the decrease in binding affinity compared 
to derivative 3.  In derivative 15, the length of the carbon chain connecting the 
protonated amine group and the aromatic rings does not allow for hydrogen 
bonding with S219, but instead the N-H group of the indole ring forms a hydrogen 
 43 
bond to S141.  However, experiments show that derivative 15 does not bind well 
to 5-HT2C, so this hydrogen bond with S141 may not in fact form.  S141 could be 
interacting instead with the backbone of TM3 or forming an interhelical hydrogen 
bond, maybe with W324, as it does in the dynamics for serotonin bound in 5-
HT2C.  Similarly, the predicted binding site of derivative 12 cannot explain the 
experimentally observed low binding affinity. 
 
Derivative 3 
 
Derivative 5 
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Derivative 7 
 
Derivative 9 
 
Derivative 11 
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Derivative 12 
 
Derivative 13 
 
Derivative 14 
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Derivative 15 
 
Derivative 16 
 
Figure 11. Side and top view of the SAR ligands.  The TMs not shown do not 
directly interact with the ligand.  The residues shown are those within 5.0 Å of the 
ligand that have more than 2 kcal of favorable interaction with the ligand.  The 
hydrogen bonds distances to the ligands, indicated by the dotted lines, are all 
between 1.85 and 2.00 Å. 
 
First, consider the trend in total binding energy. We predict derivative 5 to be 
the best and derivative 7 to be worst, which agrees with experiment. Based on 
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these interactions, proposed mutations that are predicted to decrease 
significantly the binding affinity of each ligand are listed in Table 4.   
• Deriv 3  5: This involves replacing the N-Me with N-butyl. Experimentally 
the binding constant improves from 7.0 to 4.4 nM and we calculate 15% 
improvement.  Our binding site has the butyl in hydrophobic contact with 
I142(3), I145(3), L227(5) and W324(6) leading to a predicted 4.0 kcal/mol 
improvement in binding energy over derivative 3.  Overall the cavity 
analysis is quite similar.  
• Deriv 3  14: This involves removing one CH2 from the linker connect the 
indole with the tertiary amine.  Experimentally the binding constant 
changes from 7.0 to 87 nM and we calculate a 13% weakening in binding. 
Since the tertiary amine needs to keep close to D134(3), the indole is 
moved slightly away from F223(5), leading to slightly worse binding to 
both F223(5) and D134(3). Additionally, derivative 3 has better van der 
Waals interactions with S138(3) and I332(6) than derivative 14.  Overall, 
the cavity analysis is quite similar.  
• Deriv 14  13: This involves replacing the N-Me of the indole with N-H. 
Experimentally the binding constant changes from 87 to 24 nM and we 
calculate a 2% improvement in binding.  The difference appears to be 
from the ligand solvation energy, which is more negative for derivative 14 
than derivative 13. Overall, the cavity analysis is quite similar.  
• Deriv 13  16: This involves adding an extra CHMe to the linker 
connecting the indole with the tertiary amine.  Experimentally the binding 
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constant changes from 24 to 126 nM but we calculate an 8% improvement 
in binding. Based on the 314 result we would expect that adding a CH2 
would have improved binding (this compound was not studied 
experimentally).  However, we observe that the OH is farther up in the 
pocket in derivative 16, creating better van der Waals interactions with 
I332(6) compared to derivative 13.  Additionally, derivative 16 seems to 
have better van der Waals and coulombic interactions with D134(3) than 
derivative 13.   
• Deriv 13  15: This involves adding two extra CH2 groups to the linker 
connecting the indole with the tertiary amine.  Experimentally the binding 
constant changes from 24 to 1114 nM but we calculate a 13% 
improvement in binding. The extra CH2 groups on the linker make it so the 
OH on derivative 15 cannot form a hydrogen bond with S219(5), but 
instead the NH makes a hydrogen bond with S141(3).  However, since 
derivative 15 does not bind strongly in experiment, this hydrogen bond 
may not actually exist, and S141(3) may instead interact strongly with 
W324(6), as seen in the dynamics of serotonin bound to 5-HT2C. 
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Table 4. Mutations for each ligand that are predicted to decrease binding affinity 
 
  Proposed Mutations to Decrease Binding Affinity 
Ritanserin D134A, W324A, F137A, I332T, V215T 
Metergoline D134A, S138A,  V215T, P190S 
Methiothepin D134A, S219A,  P190S 
Deriv 5 D134A, F328A, S219A, F223A 
Deriv 3 D134A, F223A, F328A, S219A 
Serotonin D134A, W324A, S138A, F328A, F223A  
Deriv 13 D134A, F328A, S219A, F223A, I332T 
Deriv 9 D134A, F328A, F223A, I332T 
Deriv 14 D134A, F328A, F223A, S219A 
Deriv 16 D134A, F223A, F328A, S219A 
Deriv 12 D134A, F328A, S219A, F223A, I332T 
Deriv 11 F328A, S219A, F223A 
Deriv 15 D134A, S141A, F328A, F223A 
Deriv 7 D134A, F328A, F223A 
 
The mutations for each ligand are listed in order of predicted decreasing effect on 
binding. 
 
Discussion of Binding Energies   
The binding energies were calculated for all of the docked ligands and compared 
to the experimental binding constants in Table 5.  Note that binding constants 
from different experiments cannot be strictly compared because different hot 
ligands at different concentrations and different temperatures were used.  
However, we find that very good binders have consistently strong binding 
constants across different experiments, even though the values are not always 
the same.   
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Table 5. The experimental binding dissociation constants (Ki) and calculated 
binding energies for ligands bound to 5-HT2C, in order of decreasing experimental 
binding strength 
 
 Calc pKa 
 
pKa 
pnlt 
Vac 
chrg 
Vac 
neut 
Lig 
solv 
chrg 
Lig 
solv 
neut 
BE 
chrg 
BE 
neut 
Exper 
Ki 
Exper 
Error 
Ritanserin 9.6 3.1 -153.1 -73.4 -59.1 -21.1 -94 -49.2 0.25 ±0.25 
Metergoline 8.8 2.0 -73.6 -69.7 -51 -18.8 -22.6 -48.9 0.29 ± 0.11 
Methiothepin 9.5 2.9 -49.9 -59.3 -44.5 -11.5 -5.4 -44.9 0.35 ± 0.35 
Deriv-5 9.8 3.4 -86.3 -56.7 -45.1 -8.9 -41.2 -44.4 4.4 ± 1.1 
Deriv-3 9.7 3.2 -86.2 -50.4 -45.9 -8.8 -40.3 -38.4 7 ± 1.6 
Serotonin 9 2.2 -92.2 -52.5 -58 -12 -34.2 -38.3 16.1 ± 1.3 
Deriv-13 10.1 3.8 -78.6 -44.9 -45.5 -6.8 -33.1 -34.3 24 ± 0.8 
Deriv-9 9.6 3.1 -74.9 -42.3 -46.9 -7.6 -28 -31.6 82 ± 34 
Deriv-14 10.1 3.8 -81.8 -45.7 -46 -8.3 -35.8 -33.6 87 ± 22 
Deriv-16 9.7 3.2 -72.2 -47.9 -44.3 -7.5 -27.9 -37.2 126 ± 19 
Deriv-12 10.2 3.9 -83.5 -51.5 -42 -7.1 -41.5 -40.5 275 ± 72 
Deriv-11 4.3 0.0 -46.4 -42.5 -9.6 -9.5 -36.8 -33.0 468 ± 450 
Deriv-15 9.8 3.4 -85.6 -49.9 -49 -7.9 -36.6 -38.6 1114 ± 41 
Deriv-7 9.7 3.2 -78.6 -40.2 -50 -8.8 -28.6 -28.2 10,000 +20,000 
 
More negative binding energies indicate stronger binding.  The Ki values and 
their errors are in units of nM.  All energy values are in kcal/mol.  The charged 
binding energy (BE chrg) is defined as the charged vacuum binding energy (vac 
chrg) minus the solvation energy of the charged ligand (lig solv chrg).  The 
neutral binding energy (BE neut) is the neutral vacuum binding energy (vac neut) 
minus the solvation energy of the neutralized ligand (lig solv neut) minus the pKa 
penalty (pKa pnlt). 
 
Calculation of binding energies was done for both the charged and 
neutralized system, and tabulated in Table 5.  Using the standard charged model 
leads to Figure 12, which plots the predicted binding energies against the 
logarithm of the experimental binding constants.   There is no correlation 
between the charged binding energies and the Ki values (R2 = 0.03).   However, 
the model in which each residue and ligand is treated as neutral leads to a rather 
good correlation between the binding energies and the Ki values (R2 = 0.70).  
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Thus, calculating the binding energy with neutral residues and ligands provides a 
significant improvement over the standard model of charged residues and 
ligands.   
Although the binding energy predictions using neutral residues lead to 
reasonable correlation with experiment, these calculations are still rudimentary.  
We consider here minimized structures with continuum solvent approximations. 
To obtain accurate binding constants we need to carry out molecular dynamics at 
300 K and include the entropic contributions to the free energy of binding.  Here 
we must also average the enthalpic parts over the molecular dynamics trajectory 
while including explicit descriptions of the solvent. 
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Figure 12.  Predicted charged (top) and neutral (bottom) binding energies vs. 
experimental binding constants with experimental errors. 
 
Comparison to 5-HT2B Predictions 
The same procedure used to predict the structure of 5-HT2C was used to predict 
the structure of 5-HT2B.  There is a 3.8 Å RMSD between the two predicted 
structures, whose alignment is seen in Figure 13.  There is close agreement 
between 5-HT2B and 5-HT2C in the rotations of TM1, TM2, TM4, TM6 and TM7.  
The conserved aspartic acid in TM3 points between TM5 and TM6 in 5-HT2C 
while it points between TM4 and TM5 in 5-HT2B.  In TM5, the conserved serine 
points into the binding pocket in 5-HT2C, while it points out toward the membrane 
in 5-HT2B.  Instead, T228 in 5-HT2B TM5, which corresponds to an alanine in 5-
HT2C, points toward the binding pocket.  TM1 is more bent in 2-HT2B than in 5-
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HT2C because there is a proline in the middle of the helix in 5-HT2B a turn away 
from two glycines.  TM4 unravels near the end of the helix in both structures 
because there are two prolines in the helix. 
 
 
Figure 13.  Alignment of the predicted 5-HT2B and 5-HT2C structures.  Indicated 
explicitly are the conserved residues Asn in TM1, Asp in TM2, Asp in TM3, Trp in 
TM4, Ser in TM5, TRP in TM6, and Asn in TM7. 
 
The bound structures for serotonin and ritanserin to 5-HT2B were predicted, 
and they are shown in Figure 14.  Experimental mutation data for serotonin 
bound to 5-HT2B can help us assess the accuracy our predicted structure and 
binding site.[47] Experimentally, serotonin binds to 5-HT2B with a binding constant 
of Ki = 9.0 nM.[48] 
• The mutation D135A in TM3 was found to create a greater than 800-fold 
decrease in serotonin binding affinity to 5-HT2B.  This agrees with the 
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prediction that D135(3) creates a salt bridge (16.9 kcal/mol) with the 
protonated amine of serotonin in 5-HT2B, as it also does in 5-HT2C. 
• An alanine substitution of T228(5) was found to cause a 90-fold decrease 
in serotonin binding affinity to 5-HT2B.  Our predicted bound structure sees 
the OH substituent of the indole in serotonin forming a hydrogen bond with 
T228(5) (3.0 kcal/mol).  The corresponding residue to this TM5 threonine 
in 5-HT2C is an isoleucine that does not interact with bound serotonin in 
our predicted structure. 
• An alanine substitution of S222(5) did not cause any effect on serotonin 
binding to 5-HT2B.  Our predicted bound structure does not have any 
interaction with this residue.  However, we predict the corresponding 
residue in 5-HT2C to form a hydrogen bond with the polar NH of the indole 
group in serotonin. 
• The mutation F341A in TM6 caused a 15-fold decrease in serotonin 
binding affinity to 5-HT2B experimentally.  Our predicted structure has good 
van der Waals interactions with F341(6) (3.4 kcal/mol).  We predict that 
the corresponding residue to this in 5-HT2C also has good van der Waals 
interactions with serotonin. 
• An alanine substitution of W337(6) was found to cause a 11-fold decrease 
in serotonin binding affinity to 5-HT2B.  Our predicted structure has 
moderate interaction with serotonin (1.1 kcal/mol), but this is not high 
enough to warrant such a large experimental decrease in binding upon 
mutation.  The corresponding tryptophan in 5-HT2C has a stronger 
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predicted interaction with serotonin, forming a hydrogen bond to the OH 
substituent of the indole in serotonin. 
 
 
 
 
 
Figure 14.  The predicted structure (side and top views) of serotonin (top) and 
ritanserin (bottom) bound to 5-HT2B.  The TMs shown do not interact directly with 
the ligand.  The residues shown are those within 5.0 Å of serotonin that have 
more than 2 kcal of favorable interaction with the ligand.  The dotted lines 
indicate hydrogen bonds with the ligand.   
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• The mutation S139A in TM3 was found to cause a 30-fold decrease in 
serotonin binding affinity to 5-HT2B.  The predicted structure has moderate 
interactions (2.1 kcal/mol) between this residue and serotonin, creating a 
very weak hydrogen bond with the protonated amine of serotonin.  The 
corresponding residue in 5-HT2C has a stronger interaction with the 
protonated amine of serotonin. 
• The substitution of serine for A187(4) was not found to have any effect on 
serotonin binding affinity to 5-HT2B.  We predict little interaction between 
this residue and serotonin, but we do predict strong hydrogen bonding 
between the backbone of I188(4) and the protonated amine of serotonin.  
We predict no such interaction in 5-HT2C.  However, this may be an 
artefact of the excessive unraveling of TM4 dues to prolines.  
• The mutation N344A in TM6 was found to cause a 7-fold decrease in 
serotonin binding affinity to 5-HT2B.  We do not see any interaction 
between this residue in our predicted structure and serotonin.  However, 
N344(6) is forming a hydrogen bond with W367(7), so it may be involved 
in structural stabilization instead of ligand binding.  These residues are 
also found in 5-HT2C, but they are not predicted to hydrogen bond. 
• The mutation D100N in TM2 was found to cause a 12-fold decrease in 
serotonin binding to 5-HT2B.  D100N(2) does not have any predicted 
interactions with bound serotonin.  However, the double mutation D100N 
in TM2 along with N367D in TM7 has no effect in serotonin binding.  Many 
studies suggest these helices do not directly bind to serotonin, but instead 
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interact through a hydrogen bonding network to indirectly affect binding 
through a conformational change in the binding pocket.  This hypothesis is 
supported by the fact that D100(2) and N376(7) are hydrogen bonding in 
the predicted structure, and experiments show that if the identities of the 
two amino acids are switched, effectively retaining the hydrogen bond, the 
original binding constants to serotonin are maintained.  These two amino 
acids are also hydrogen bonded in 5-HT2C, with no interaction with 
serotonin. 
Comparison of the predicted 5-HT2B serotonin bound structure to mutagenesis 
experiments shows some good agreement with experiment, but there are also 
some discrepancies.  The fact that serotonin makes a hydrogen bond with the 
backbone of TM4 probably means that TM4 is packed too closely to TM3, or that 
TM4 has unraveled too much.  Also, mutagenesis experiments suggest stronger 
interactions between serotonin and the residues S139(3) and W337(6).  There 
could be hydrogen bonding to S139(3) and better van der Waals interactions with 
serotonin if TM3 were rotated more closely to the same angle as it is in 5-HT2C.  
Despite these inconsistencies, there are strong similarities to the predicted 5-
HT2C structure, with the differences in predicted serotonin binding between the 
two receptors primarily due to the different rotation of TM5.   
Our predicted serotonin binding site for 5-HT2B agrees more closely with 
mutagenesis experiments than do homology models of 5-HT2B.  A study 
comparing homology models of 5-HT based on bacteriorhodopsin and bovine 
rhodopsin concluded that the bacteriorhodopsin-based model correlated better 
 58 
with experimental mutagenesis data.[47] According to this bacteriorhodopsin-
based homology model of 5-HT2B, D135(3), S139(3), F341(6) and N344(6) make 
direct contacts with serotonin.  Additionally, W131(3), F138(3), F341(6) and 
F365(7) form an aromatic box surrounding serotonin in the homology model.  
This model does not show any significant interaction between serotonin and TM5, 
while our model shows hydrogen bonding between serotonin and T228(5).  
Experiments suggest that T228(5) is very important in binding serotonin, as 
evidenced by the fact that a mutation to alanine causes a 90-fold decrease in 
serotonin binding.  The homology model has serotonin forming a hydrogen bond 
with N344(6) instead of with T228(5), although experiments only show a 7-fold 
decrease of binding from the N344A mutation.  Additionally, the homology model 
shows no interaction with W337(6), while our model has moderate interactions 
the residue, which agrees with experiment, because the W337A mutation causes 
a 12-fold decrease in serotonin binding.  Thus, overall, our predicted serotonin 
binding site of 5-HT2B correlates better with the available experimental data than 
does a bacteriorhodopsin-based homology model. 
The binding site for one antagonist, ritanserin, was predicted for 5-HT2B.  
Experimentally, ritanserin binds to 5-HT2B with a binding constant of                    
Ki = 1.6 nM.[48] The most important contacts are as follows. 
• The protonated nitrogen of the piperidine forms a salt bridge with D135(3) 
(16.4 kcal/mol).  
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• The aromatic thiazolo-pyrimidine group has strong van der Waals 
interactions with W131(3) (7.8 kcal/mol), V348(6) (5.0 kcal/mol), and 
E363(7) (2.1 kcal/mol). 
• The flourophenyl groups have strong van der Waals interactions with 
I345(6) (3.2 kcal/mol), P191(4) (2.6 kcal/mol), and F138(3) (2.0 kcal/mol). 
This predicted binding site for ritanserin in 5-HT2B has little in common with the 
predicted binding site for ritanserin in 5-HT2C, except that they both interact with 
TM3 and TM6, and both have salt bridges between ritanserin and the aspartic 
acid on TM3. 
The binding constants were calculated for serotonin and ritanserin bound to 
5-HT2B, and the results are shown in Table 6.  The calculated binding constants 
correctly predict that ritanserin binds more strongly than serotonin to 5-HT2B.  
When the calculated binding constants for 5-HT2B are compared with those for  
5-HT2C, the binding constants for 5-HT2C are stronger than those for 5-HT2B.  
However, the binding constants for the two receptors are much closer together 
once the complexes are neutralized. 
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Table 6. The experimental binding dissociation constants (Ki) and calculated 
binding energies for ligands bound to 5-HT2B, in order of decreasing experimental 
binding strength 
 
 Calc pKa 
 
pKa 
pnlt 
Vac 
Chrg 
Vac 
neut 
Lig 
solv 
chrg 
Lig 
solv 
neut 
BE 
chrg 
BE 
neut 
Exper 
Ki 
Exper 
Error 
Ritanserin 9.6 3.1 -127.4 -60.4 -56.7 -20.9 -70.7 -36.4 1.6 ±0.7 
Serotonin 9 2.2 -108.7 -46.7 -57.5 -11 -51.2 -33.5 9 ±1.9 
 
More negative binding energies indicate stronger binding.  The Ki values and 
their errors are in units of nM.  All energy values are in kcal/mol.  The charged 
binding energy (BE chrg) is defined as the charged vacuum binding energy (vac 
chrg) minus the solvation energy of the charged ligand (lig solv chrg).  The 
neutral binding energy (BE neut) is the neutral vacuum binding energy (vac neut) 
minus the solvation energy of the neutralized ligand (lig solv neut) minus the pKa 
penalty (pKa pnlt). 
 
 
Conclusion 
We find good agreement between the calculated binding sites of the predicted 
ligand-protein bound complexes of 5-HT2C and experimental binding constants.  
We also find many similarities between the predicted serotonin binding site for 5-
HT2C and mutagenesis experiments for 5-HT2A.  Additionally, comparison of the 
predicted 5-HT2C structure with a preliminary prediction of the 5-HT2B structure 
along with mutation experiments on serotonin bound in 5-HT2B reveals a great 
deal of similarity between the two structures.  This suggests that the 3D protein 
structure predicted by the Membstruk method is sufficiently accurate for drug 
design.  Dynamics of serotonin bound in 5-HT2C in an explicit lipid bilayer show 
the predicted binding site to be stable during 5 ns of simulation.  The predicted 
binding site for serotonin leads to the suggested mutations S138A, S141A, 
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S219A, F223A, F328A and W324A and I332A, which are predicted to all cause a 
decrease in binding energies.  Mutation experiments for other ligands, including 
strongly binding antagonists and a series of psilocybin analogs, are also 
proposed.  Thus, a wealth of data is now available to further validate the 
proposed structure and binding sites of 5-HT2C.  The good agreement between 
experiment and the predicted bound structures indicates that the procedures are 
useful for studying other systems with less experimental data. 
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Chapter 2 
 
SuperBiHelix: A New Method for Predicting an 
Ensemble of Low-Lying GPCR Structures 
 
 
Abstract 
A new procedure called SuperBiHelix has been developed for GPCR structure 
prediction.  It predicts an ensemble of low-lying structures.  SuperBiHelix places 
predicted TM helices in an experimental template, and samples the tilt and 
sweep angles of the helices along with the rotation of the helices along the 
helical axes.  The procedure was validated on the β2-adrenergic receptor and 
A2A adenosine receptor experimental crystal structures.  The SuperBiHelix 
procedure will make it possible to more accurately predict structures of GPCRs 
that are dissimilar to available experimental structures. 
 
Introduction 
The introduction of the BiHelix procedure into the GPCR structure prediction 
method allowed for more accurate structure prediction.  However, the BiHelix 
procedure relies heavily on the experimental template in which the helices are 
placed, for the only degree of freedom sampled is the rotation of each helix along 
its own axis.  A new procedure has been developed, SuperBiHelix, which 
samples the sweep angle and tilt angle of each helix, in addition to the rotation 
about their own axes.  This sampling of additional degrees of freedom will make 
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the structure prediction less dependent on the template, and therefore less 
dependent on any experimental input.  Thus, it will allow more accurate 
prediction of structures for receptors dissimilar to any available experimental 
structure.  Finally, it has the additional advantage of predicting more low-lying 
structures, which could lead to insights on GPCR activation.  
 The procedure was tested by placing the helices of one experimental 
structure into another experimental template, and running SuperBiHelix to 
determine whether the helices recognize their original template.  After the 
procedure was validated, it was used on experimental helices in their original 
structures to see what other low-lying structure arise.  
 
Methodology 
After the helix lengths and shapes are predicted, they are placed in an 
experimental GPCR bundle template, which is defined by a system of 
coordinates shown in Figure 15.  Each experimental template has 42 degrees of 
freedom: x, y, z, θ, φ and η values for each of the seven TM helices.  The helices 
have kinks and bends, so the helical axis is defined as its moment of least inertia.  
The hydrophobic center is the residue that crosses z = 0, which is defined as the 
plane that runs through the center of the lipid bilayer, and it is either calculated 
from the protein’s hydrophobic profile or by homology.  The x-axis is defined 
along the axis from the center of TM3, which is in the middle of the bundle, to the 
center of TM2 in the mid-plane (z = 0).  The definitions of the x-axis and z-axis 
implicitly define the y-axis.  The x and y values of the helices (where the 
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hydrophobic centers cross z = 0), are defined by the experimental template, and 
are not sampled by SuperBiHelix.  The degrees of freedom that are sampled are 
θ, the tilt angle of the helix; φ, the sweep angle of the helix; and η, the rotation of 
the helix around the helical axis. 
 
 
Figure 15.  The coordinates used to describe the orientation of the seven helices 
in a GPCR bundle. 
 
 The SuperBiHelix program takes an input GPCR bundle file, and determines 
its template.  It then varies the θ, φ and η values.  However, even if just sampling 
a small number of angles for each degree of freedom, for example three, that 
would lead to (3*3*3)7 ≈ 1010 possible configurations for which to predict the side 
chains and calculate the energy.  This is far too computationally expensive.  
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However, if the energy is approximated to be made up of only interactions 
between two helices, the calculation is more tractable.  A seven-helix GPCR TM 
bundle has twelve strongly interacting pairs: TM1-TM2, TM1-TM7, TM2-TM3, 
TM2-TM4, TM2-7, TM3-TM4, TM3-TM5, TM3-TM6, TM3-TM7, TM4-TM5, TM5-
TM6 and TM6-TM7.  For each of these twelve interacting pairs, θ, φ and η are 
sampled with the other helices absent in order to get the bihelical energies.  
SCREAM is used to predict the side chain placements, then the side chains are 
minimized for 10 steps with the backbone fixed.  This procedure is illustrated in 
Figure 16. 
 
  
Figure 16.  Diagram of the SuperBiHelix method, in which the seven-helix TM 
bundle is split into twelve helix pairs, and the θ, φ and η values for each helix in 
the pair is sampled with the other helices not present. 
 
 Once the bihelical energies have been determined for all possible 
combinations of θ, φ and η, the energy of the entire bundle for each possible 
conformation must be calculated. The bihelical energies are decomposed into 
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intrahelical and interhelical components.  The energy of the entire complex is 
then calculated as  
! 
Eintra " ,# ,$ ( ) =
1
Ni
Ei, intra
ij
j= Ji ,1 , j> i
J i ,Ni
%
i=1
7
% "i," j ,#i,# j ,$i,$ j( ),
Einter " ,# ,$ ( ) = Einterij "i," j ,#i,# j ,$i,$ j( )
j= Ji ,1 , j> i
J i ,Ni
%
i=1
7
% ,
Etotal " ,# ,$ ( ) = Eintra " ,# ,$ ( ) + Einter " ,# ,$ ( ),
 
! 
" = "
1
,"
2
,"
3
,"
4
,"
5
,"
6
,"
7( ),
# = #
1
,#
2
,#
3
,#
4
,#
5
,#
6
,#
7( ),
$ = $
1
,$
2
,$
3
,$
4
,$
5
,$
6
,$
7( ),
 
where Ni is the number of helices interacting with helix i, and Ji,k is the kth 
neighbor of helix i.  Although the calculation of the energy of a complex based on 
its bihelical energies is very fast, the calculation of all possible configurations is 
still too computationally expensive.  In practice, the smallest number of 
conformations sampled would be three values of θ, five values of φ and five 
values of η, which would lead to (3*5*5)7 ≈1013 total bundle conformations.  Thus, 
a procedure must be developed to determine which conformations for each helix 
are most favorable, so that fewer total bundle energies have to be calculated. 
 In order to determine the best conformations for each helix that will lead to 
the lowest energy bundles, the seven-helix bundle is partitioned into three 
quadhelix bundles, as shown in Figure 17.   
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Figure 17.  In order to determine best conformations for each helix that will lead 
to the lowest energy bundles, the seven helix bundle is partitioned into three 
quadhelix bundles: TM1-TM2-TM3-TM7, TM2-TM3-TM4-TM5 and TM3-TM5-
TM6-TM7. 
 
Next, the total bihelical energies of the three quadhelix bundles are calculated.  
This is feasible because only 3*(3*5*5)4 ≈ 108 bundle energies must be calculated. 
The 2000 structures with the lowest energy for each quadhelix are listed by 
increasing energy.  Then, the conformations are ranked for each helix, using the 
following protocol: 
• For TM1, each unique TM1 conformation (η1,θ1,φ1) in the                     
TM1-TM2-TM3-TM7 bundle list is taken. 
• For TM2, each unique TM2 conformation (η2,θ2,φ2) in the                     
TM1-TM2-TM3-TM7 bundle list is alternated with each unique TM2 
conformation in the TM2-TM3-TM4-TM5 bundle list. 
• For TM3, each unique TM3 conformation (η3,θ3,φ3) in the                     
TM1-TM2-TM3-TM7 bundle list is taken in alternation with each unique 
TM3 conformation in the TM2-TM3-TM4-TM5 bundle list and each unique 
TM3 conformation in the TM3-TM5-TM6-TM7 bundle list. 
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• For TM4, each unique TM4 conformation (η4,θ4,φ4) in the                     
TM2-TM3-TM4-TM5 bundle list is taken. 
• For TM5, each unique TM5 conformation (η5,θ5,φ5) in the                     
TM2-TM3-TM4-TM5 bundle list is alternated with each unique TM5 
conformation in the TM3-TM5-TM6-TM7 bundle list. 
• For TM6, each unique TM6 conformation (η6,θ6,φ6) in the                     
TM3-TM5-TM6-TM7 bundle list is taken. 
• For TM7, each unique TM7 conformation (η7,θ7,φ7) in the                     
TM1-TM2-TM3-TM7 bundle list is alternated with each unique TM7 
conformation in the TM3-TM5-TM6-TM7 bundle list. 
Finally, from each individual helical conformation list, the best 36 conformations 
for each helix are used to calculate the energy of 367 ≈ 8 x 1010 full bundles, and 
output the 1000 best energy structures from this procedure.  
 In a procedure called SuperComBiHelix, these top 1000 helical bundles are 
built and the side chains are reassigned, given that they will take different 
conformations than in the bihelical mode.  Then the structure is minimized for 10 
steps.  The energy ranking will be different in SuperComBiHelix than 
SuperBiHelix because all seven helices are present instead of just two at a time.  
This procedure results in an ensemble of low-lying structures.  Examination of 
the low-lying structures shows which helices are flexible, and may give insight 
into activation.   
 Extensive testing on these methods, shown in the Validation section, lead to 
several improvements in the procedure. During the side chain prediction steps in 
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SuperBiHelix and SuperComBiHelix, SCREAM must be used with a 0.5 Å 
resolution library instead of the 1.0 Å resolution library that is the default for 
SCREAM.  Additionally, the best results arise from alanizing the final two 
residues of the C- and N-termini for each helix during the SuperBiHelix step.  
Then, before the SuperComBiHelix step, the alanized residues are mutated back 
to their original residues for the building of the full bundles.   This step reduces 
artificial long range electrostatic interactions between charged groups that would 
be located in the polar head group region of the lipid bilayer. 
 
Validation 
SuperBiHelix on Crystal Helices in an Incorrect Template 
The SuperBiHelix and SuperComBiHelix methods were tested on the               
β2-adrenergic receptor[5] in the A2A adenosine receptor[6] template, and vice 
versa.  The differences between the x, y, θ, φ and η values for the two templates 
are given in Table 7. 
 
Table 7.  The differences between the A2A adenosine receptor and β2-adrenergic 
receptor templates 
 
A2A adenosine to β2-adrenergic template 
TM x (Å) y (Å) θ  (o) φ  (o) η (o) 
1 2.0 1.7 6.3 17.9 4.8 
2 0.2 0.0 7.7 2.4 -18.8 
3 0.0 0.0 4.9 2.0 -13.2 
4 -1.5 -0.4 -4.1 -3.0 -9.2 
5 0.1 -0.6 -1.2 14.9 0.0 
6 0.8 0.0 10.8 -24.8 0.9 
7 -0.1 1.1 4.1 3.1 2.6 
 
The system of coordinates is described in Figure 15. 
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Table 7 reveals that x and y have only a small amount of variation between 
templates, supporting the fact that the SuperBiHelix procedure does not sample x 
or y.  It also shows that φ and η vary more among templates than θ, so more φ 
and η values will need to be sampled than θ values. 
 The first test performed was to take the helices and template of the β2-
adrenergic receptor, and give the template the φ and θ values of the A2A 
adenosine receptor.  For all of the test runs, the helices in the original crystal 
structures were minimized separately without the other helices present so that 
the procedure was not biased toward the crystal structure.  Then θ was sampled 
with values of −10o, 0o and 10o, while φ was sampled with values of −30o, −15o, 
0o, 15o and 30o.  The results of this test, using both 1.0 Å and 0.5 Å SCREAM 
libraries, are shown in Table 8.  Table 8 clearly shows that the use of the 0.5 Å 
SCREAM library instead of the 1.0 Å SCREAM library is necessary for 
SuperBiHelix and SuperComBiHelix.  When the 1.0 Å SCREAM library is used, 
the structure goes from 1.9 Å backbone RMSD to the crystal structure to a 1.4 Å 
backbone RMSD.  When the 0.5 Å SCREAM library is used, the structure goes to 
a 0.9 Å backbone RMSD.  The closest structure to the crystal structure that the 
procedure could possibly produce, given the angles sampled, has a 0.8 Å 
backbone RMSD.  Additionally, with the 0.5 Å SCREAM library, the crystal 
structure is one of the best energy structures, while it is not with the 1.0 Å 
SCREAM library. 
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Table 8. SuperComBiHelix results for β2-adrenergic receptor with A2A adenosine 
template φ and θ values 
 
1.0 Å SCREAM library 
θ H1 H2 H3 H4 H5 H6 H7 φ H1 H2 H3 H4 H5 H6 H7 
Energy 
(kcal/mol) 
RMSD 
(Å) 
 10 0 0 0 0 10 10  0 -15 0 -15 15 -15 15 150.3 1.4 
 10 0 0 0 0 10 10  0 -15 0 0 15 -15 15 155.4 1.4 
 10 0 0 0 0 10 10  0 -15 0 -30 15 -15 15 164.8 1.4 
 10 0 0 0 0 10 0  -30 0 0 -30 0 -30 15 177.3 2.8 
 10 0 0 0 0 10 10  0 0 0 -15 15 -15 15 178.7 1.4 
 10 0 0 0 0 10 0  0 0 0 -15 15 -15 15 181.1 1.4 
 10 0 0 0 0 10 10  0 0 0 -30 15 -15 15 181.7 1.4 
 10 0 0 0 0 10 0  0 0 0 -30 0 -30 15 182.6 1.5 
 10 0 0 0 0 10 0  0 0 0 -30 15 -15 15 183 1.4 
 10 0 0 0 0 10 0  -15 0 0 -15 15 -30 15 184.8 2 
 6 8 5 -4 -1 11 4  18 2 2 -3 15 -25 3 189.7 0 
 10 10 0 0 0 10 0  15 0 0 0 15 -30 0 223.4 0.8 
 0 0 0 0 0 0 0  0 0 0 0 0 0 0 446.4 1.9 
 
0.5 Å SCREAM library 
θ  H1 H2 H3 H4 H5 H6 H7 φ  H1 H2 H3 H4 H5 H6 H7 
Energy 
(kcal/mol) 
RMSD 
(Å)  
 10 10 0 0 0 10 10  15 0 0 -15 0 -15 15 57.2 0.9 
 6 8 5 -4 -1 11 4  18 2 2 -3 15 -25 3 60.6 0 
 10 0 0 0 0 10 0  0 0 0 -30 15 -30 0 79 1.4 
 10 10 0 10 0 10 0  0 -15 -15 -15 0 -30 0 93.4 1.7 
 10 10 0 0 0 10 10  15 0 0 -15 15 -15 15 93.6 0.8 
 10 0 0 0 0 10 0  0 0 0 -15 15 -30 0 96.1 1.4 
 10 10 0 0 0 10 0  15 0 0 0 0 -15 15 96.9 0.9 
 10 10 0 0 0 10 0  15 0 0 -15 15 -30 -15 98.4 0.9 
 0 0 0 0 0 10 0  15 0 0 -15 15 -30 0 101.1 1.1 
 10 10 0 10 0 10 0  15 0 15 -30 15 -30 0 102.3 1.4 
 10 10 0 0 0 10 0  15 0 0 -30 0 -15 15 102.3 1 
 10 10 0 0 0 10 0  15 0 0 0 15 -30 0 111.6 0.8 
 0 0 0 0 0 0 0  0 0 0 0 0 0 0 309.9 1.9 
 
The RMSD is the backbone RMSD to the β2-adrenergic receptor crystal structure.  
The structure highlighted in orange is the crystal structure.  The structure 
highlighted in green is the original structure in the incorrect template.  The 
structure highlighted in yellow is the closest structure to the crystal structure 
given the angles sampled.  
 
 For the same test performed on the A2A adenosine helices with the φ and θ 
values of the β2-adrenergic template, using the 0.5 Å SCREAM library, the 
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structure goes from a 2.0 Å backbone RMSD to the crystal structure to a 0.9 Å 
backbone RMSD.  Thus, the 0.5 Å SCREAM library will be used for all 
SuperBiHelix and SuperComBiHelix runs.  The next test was to take the helices 
and template of the A2A adenosine receptor, and give them the η, φ and θ values 
of the β2-adrenergic template.  The x and y values were still from the A2A 
adenosine template.  SuperBiHelix and SuperComBiHelix were run, sampling θ 
with values of −10o, 0o and 10o, φ with values of −30o, −15o, 0o, 15o and 30o, and 
η with values of −30o, −15o, 0o, 15o and 30o.  The results are given in Table 9.  
 
 
Table 9. SuperComBiHelix results for the A2A adenosine receptor with β2-
adrenergic template φ, θ and η values 
 
θ H1 H2 H3 H4 H5 H6 H7 φ H1 H2 H3 H4 H5 H6 H7 η H1 H2 H3 H4 H5 H6 H7 
Energy 
(kcal/mol) 
RMSD 
(Å) 
 -6 -8 -5 4 1 -11 -4  -18 -2 -2 3 -15 25 -3  -5 19 13 9 0 -1 -3 88.2 0.2 
 -10 -10 0 0 10 -10 0  -30 0 0 -15 -15 -30 0  -15 15 15 15 0 0 0 112.1 1.1 
 -10 -10 -10 10 0 -10 0  -30 -15 0 -30 -15 0 0  -15 15 15 15 0 0 -15 116.4 1 
 -10 -10 0 0 10 -10 0  -30 0 0 0 -15 -30 0  -15 15 15 15 0 0 0 118.2 1.1 
 -10 -10 -10 10 0 -10 0  -30 -15 0 -30 -15 -15 0  -15 15 15 15 0 0 0 125.8 1 
 -10 -10 -10 10 0 -10 0  -30 -15 -15 -30 -15 15 0  -15 15 15 15 0 0 -15 132.6 1 
 0 -10 -10 10 0 -10 0  -30 -15 0 -30 -15 0 0  0 15 15 15 0 0 -15 134.9 1 
 0 -10 -10 0 0 -10 0  -30 -30 0 -30 -15 15 -15  0 15 15 0 0 0 0 134.9 1.1 
 -10 -10 -10 10 0 -10 0  -30 -15 0 -30 -15 15 0  -15 15 15 15 0 0 -15 136.8 0.9 
 0 -10 -10 0 0 -10 0  -30 -30 0 -30 -15 0 -15  0 15 15 0 0 0 0 138.5 1.1 
 -10 -10 0 0 10 -10 0  -30 0 0 -15 -15 -30 -15  -15 15 15 15 0 0 0 138.5 1.1 
 -10 -10 0 0 0 -10 0  -15 0 0 0 -15 30 0  0 15 15 15 0 0 0 257.6 0.8 
 0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0 794.6 2 
 
The RMSD is the backbone RMSD to the A2A adenosine receptor crystal 
structure.  The structure highlighted in orange is the crystal structure.  The 
structure highlighted in green is the original structure in the incorrect template.  
The structure highlighted in yellow is the closest structure to the crystal structure 
given the angles sampled.  
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Table 9 shows that SuperBiHelix works on the A2A adenosine receptor with β2-
adrenergic template φ, θ and η values: the structure goes from a 2.0 Å backbone 
RMSD to the crystal structure to a 1.1 Å backbone RMSD, with the lowest 
possible RMSD being 0.8 Å. 
 For the same test performed on the helices and template of the β2-
adrenergic receptor with the η, φ and θ values of the A2A adenosine template, the 
results are not as promising, as shown in Table 10.   
 
Table 10. SuperComBiHelix results for the β2-adrenergic receptor with A2A 
adenosine template φ, θ and η values 
 
θ H1 H2 H3 H4 H5 H6 H7 φ H1 H2 H3 H4 H5 H6 H7 η  H1 H2 H3 H4 H5 H6 H7 
Energy 
(kcal/mol) 
RMSD 
(Å) 
 6 8 5 -4 -1 11 4  18 2 2 -3 15 -25 3  5 -19 -13 -9 0 1 3 55.6 0.1 
 10 0 0 0 0 10 0  -15 0 0 -30 15 -30 0  30 -15 -15 0 0 0 0 89.5 2.1 
 10 0 0 0 0 10 10  0 -15 0 -30 -15 0 15  0 -15 -15 0 -15 0 0 92.5 1.7 
 10 0 0 0 0 10 0  0 -15 0 -30 15 -30 -15  0 -15 -15 0 0 0 0 95 1.5 
 0 0 0 0 0 10 0  -30 0 0 -30 -15 -30 0  -30 -15 -15 0 -15 0 0 95.4 2.7 
 10 0 0 0 0 10 10  -30 -15 0 -30 -15 -30 15  -15 -15 -15 0 -15 0 -15 99.8 2.9 
 10 0 0 0 0 10 0  -15 0 0 -30 15 -30 0  15 -15 -15 0 0 0 0 100.7 2.1 
 0 0 0 0 0 10 0  0 -15 0 -30 15 -30 -15  0 -15 -15 0 0 0 0 103.3 1.4 
 10 0 0 0 0 10 0  0 0 0 -30 -15 -30 0  15 -15 -15 0 -15 0 0 104.4 1.7 
 10 0 -10 10 0 10 10  -30 -15 0 -30 0 -30 15  0 -30 -15 0 0 0 0 106.4 3 
 10 0 0 0 0 10 10  -30 -15 0 -30 -15 0 15  0 -15 -15 0 -15 0 0 106.5 2.9 
 10 10 0 0 0 10 0  15 0 0 0 15 -30 0  0 -15 -15 -15 0 0 0 108.3 0.8 
 0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0 437.2 1.9 
 
The RMSD is the backbone RMSD to the β2-adrenergic receptor crystal structure.  
The structure highlighted in orange is the crystal structure.  The structure 
highlighted in green is the original structure in the incorrect template.  The 
structure highlighted in yellow is the closest structure to the crystal structure 
given the angles sampled.  
 
As Table 10 reveals, SuperBiHelix and SuperComBiHelix fail when run on the 
β2-adrenergic receptor helices with A2A adenosine template φ, θ and η values: 
the structure goes from a 1.9 Å backbone RMSD to the crystal structure to a 2.1 
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Å backbone RMSD.  There must be an explanation for why the SuperBiHelix 
procedure fails with β2-adrenergic receptor helices in the A2A adenosine template, 
but succeeds with A2A adenosine receptor helices in the β2-adrenergic.  
Inspection of the helices of the two receptors reveals that the β2-adrenergic 
helices have more charged residues near the ends of the helices than the A2A 
adenosine helices, as shown in Figure 18. 
 
  
 A2A adenosine receptor:    β2-adrenergic receptor: 
 4 charged termini residues   10 charged termini residues 
 
Figure 18.  A comparison of charged termini residues in the A2A adenosine and 
β2-adrenergic receptors.  A terminus residue is defined to be any residue within 
two residues of the end of a TM helix.  Charged residues are ARG, GLU, ASP 
and LYS. 
 
 The A2A adenosine TM helices have four charged termini residues, where a 
terminus residue is defined to be any residue within two residues of the end of a 
helix, while the β2-adrenergic TM helices have ten charged termini residues.  
Coulombic interactions between charged residues at the termini are sensitive to 
 75 
small changes in helix orientation.  Plus, these termini residues are located in the 
polar head group region of the lipid bilayer, which would provide significant 
charge screening.  Based on this difference in the number of charged residues, a 
SuperBiHelix run was again performed on the β2-adrenergic receptor helices 
with A2A adenosine template φ, θ and η values, but with the final two residues, 
excepting GLY or PRO, of each helix mutated to alanine.  The results of this test 
are shown in Table 11.  
 
Table 11. SuperComBiHelix results for the β2-adrenergic receptor with A2A 
adenosine template φ, θ and η values, with any residue within two residues of the 
end of a TM helix mutated to alanine during the SuperBiHelix and 
SuperComBiHelix procedures 
 
θ H1 H2 H3 H4 H5 H6 H7 φ H1 H2 H3 H4 H5 H6 H7 η  H1 H2 H3 H4 H5 H6 H7 
Energy 
(kcal/mol) 
RMSD 
(Å) 
 6 8 5 -4 -1 11 4  18 2 2 -3 15 -25 3  5 -19 -13 -9 0 1 3 369.9 0 
 -10 0 0 0 0 10 0  15 0 0 -30 -15 -30 0  -15 -15 -15 0 -15 0 0 388.6 2 
 10 10 0 10 0 10 0  15 0 0 -30 -15 -30 0  0 -15 -15 0 0 0 0 402.3 1.5 
 0 0 0 0 0 10 0  0 0 0 -30 -15 -30 0  15 -15 -15 0 -15 0 0 403 1.7 
 0 0 0 0 0 10 0  0 0 0 -30 -15 -30 0  0 -15 -15 0 -15 0 0 404 1.6 
 10 10 0 0 0 10 0  15 0 0 -15 -15 -30 0  0 -15 -15 -15 0 0 0 409.2 1.2 
 10 10 0 0 0 10 0  15 0 0 -30 -15 -30 0  0 -15 -15 -15 0 0 0 419.4 1.2 
 10 10 0 0 0 10 0  15 0 0 -15 0 -15 15  0 -15 -15 0 0 0 0 423.4 0.9 
 10 10 0 0 0 10 0  15 0 0 -30 0 -30 0  0 -15 -15 -15 -15 0 0 424.3 1 
 10 10 0 0 0 10 0  0 0 0 -15 -15 -30 0  0 -15 -15 -15 0 0 0 425.8 1.5 
 10 10 0 0 0 10 0  15 0 0 -30 -15 -30 0  0 -15 -15 -15 -15 0 0 426.1 1.2 
 10 10 0 0 0 10 0  15 0 0 0 15 -30 0  0 -15 -15 -15 0 0 0 450.9 0.8 
 0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0 768.7 1.9 
 
The RMSD is the backbone RMSD to the β2-adrenergic receptor crystal structure.  
The structure highlighted in orange is the crystal structure.  The structure 
highlighted in green is the original structure in the incorrect template.  The 
structure highlighted in yellow is the closest structure to the crystal structure 
given the angles sampled.  
 
 The alanization of the termini residues improves the results a little bit for the 
β2-adrenergic receptor in the A2A adenosine template, in that the backbone 
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RMSD values of the top ten SuperComBiHelix structures to the β2-adrenergic 
receptor crystal structure are less than or equal to 2.0 Å.  However, the best 
energy structure still has a 2.0 Å RMSD from the crystal structure, which is worse 
than the original structure in the incorrect template.  So, the procedure was once 
again changed so that the termini are alanized for the SuperBiHelix procedure, 
but then mutated back to the original residues for the SuperComBiHelix 
procedure.  The results for this test are shown in Table 12. 
 
Table 12. SuperComBiHelix results for the β2-adrenergic receptor with A2A 
adenosine template φ, θ and η values, with any residue within two residues within 
the end of a TM helix mutated to alanine during the SuperBiHelix procedure 
 
θ H1 H2 H3 H4 H5 H6 H7 φ H1 H2 H3 H4 H5 H6 H7 η  H1 H2 H3 H4 H5 H6 H7 
Energy 
(kcal/mol) 
RMSD 
(Å) 
 6 8 5 -4 -1 11 4  18 2 2 -3 15 -25 3  5 -19 -13 -9 0 1 3 55.6 0 
 10 10 0 0 0 10 0  15 0 0 -15 0 -30 0  0 -15 -15 -15 0 0 0 78 0.9 
 0 0 0 0 0 10 0  0 0 0 -30 -15 -30 0  0 -15 -15 0 -15 0 0 81.7 1.6 
 10 10 0 0 0 10 0  15 0 0 -15 15 -30 0  15 -15 -15 -15 0 0 0 92.6 0.9 
 10 10 0 0 0 10 10  0 0 0 -15 0 -15 15  0 -15 -15 0 0 0 0 94 1.3 
 10 10 0 10 0 10 0  15 0 0 -30 15 -30 0  15 -15 0 -15 -15 0 0 95.6 1.3 
 10 10 0 0 0 10 10  0 -15 0 -15 0 -15 15  0 -15 -15 15 0 0 0 95.6 1.4 
 0 0 0 0 0 10 0  0 0 0 -30 -15 -30 0  0 -15 -15 -15 0 0 0 96.8 1.6 
 10 10 0 0 0 10 10  0 -15 0 -30 0 -15 15  0 -15 -15 0 0 0 0 96.9 1.4 
 10 10 0 0 0 10 10  15 0 0 -30 -30 -15 15  0 -15 -15 0 -15 0 0 96.9 1.4 
 10 10 0 0 0 10 10  0 0 0 -30 -15 -15 15  0 -15 -15 -15 -15 0 0 99 1.5 
 10 10 0 0 0 10 0  15 0 0 0 15 -30 0  0 -15 -15 -15 0 0 0 108.3 0.8 
 0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0 437.2 1.9 
 
The original helices, with all charged termini residues present, are then used for 
the SuperComBiHelix procedure.  The RMSD is the backbone RMSD to the β2-
adrenergic receptor crystal structure.  The structure highlighted in orange is the 
crystal structure.  The structure highlighted in green is the original structure in the 
incorrect template.  The structure highlighted in yellow is the closest structure to 
the crystal structure given the angles sampled.  
 
Table 12 shows that the procedure in which the termini are alanized for 
SuperBiHelix and dealanized for the SuperComBiHelix works well.  With          
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β2-adrenergic receptor with A2A adenosine template φ, θ and η values, the 
backbone RMSD to the β2-adrenergic receptor crystal structure goes from 1.9 Å 
to 0.9 Å, with the closest possible RMSD given the angles sampled being 0.8 Å.  
Thus, the procedure will be permanently changed to include the alanization and 
dealanization steps. 
 All of the tests so far have kept the x, y and z values of the original template 
while giving the template the incorrect φ, θ and η values.  However, while we 
have methods to calculate z based on the primary sequence, we do not have any 
way of calculating x or y for a receptor with an unknown structure.  Thus, for the 
next test, β2-adrenergic helices were given the x, y, φ, θ and η values the A2A 
adenosine template, and SuperBiHelix and SuperComBiHelix were run, with the 
results seen in Table 13.  As seen in Table 13, when the x and y values are 
incorrect, the SuperBiHelix and SuperComBiHelix procedures causes the 
backbone RMSD to the β2-adrenergic receptor crystal structure to go from 2.0 Å 
to 1.6 Å, a modest improvement.  The lowest possible RMSD, given the angles 
sampled, is 1.2 Å. The procedure does not do a good job at predicting the 
conformation of TM1, as seen in an alignment between the crystal structure and 
the structures before and after SuperBiHelix and SuperComBiHelix, shown in 
Figure 19.  This is due to the fact that TM1 has the fewest interactions with other 
helices, because it does not have direct interaction with TM3 like the other TM 
helices.  Additionally, Table 7 shows that in the x and y values, which are not 
sampled by SuperBiHelix, TM1 has larger deviations between the β2-adrenergic 
and A2A adenosine templates than any other helix. 
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Table 13. SuperComBiHelix results for the β2-adrenergic receptor with A2A 
adenosine template φ, θ, η, x and y values 
 
θ H1 H2 H3 H4 H5 H6 H7 φ H1 H2 H3 H4 H5 H6 H7 η  H1 H2 H3 H4 H5 H6 H7 
Energy 
(kcal/mol) 
RMSD 
(Å) 
 0 0 0 0 0 10 0  0 0 0 -30 0 -30 -15  -30 -15 -15 -30 -15 0 15 164.6 1.6 
 0 0 0 0 0 10 0  0 0 0 -30 0 -30 -30  -30 -15 -15 -30 -15 0 0 176.6 1.6 
 0 0 0 0 0 10 0  0 0 0 -30 0 -30 15  -30 -15 -15 -30 -15 -15 15 177.7 1.7 
 0 0 0 0 0 10 0  -15 0 0 -30 0 -30 -30  -30 -15 -15 -30 -15 -15 0 187.2 2 
 0 0 0 0 0 10 0  0 15 0 -30 0 -30 -15  -30 -15 -15 -30 -15 0 15 188.2 1.7 
 0 0 0 0 0 10 0  -15 0 0 -30 0 -30 30  -30 -15 -15 -30 -15 -15 15 196.7 2.1 
 0 0 0 0 0 10 0  0 0 0 -30 0 -30 -30  -30 -15 -15 -30 -15 -15 0 198.9 1.6 
 0 0 0 0 0 10 0  -15 0 0 -30 -15 -30 -30  -30 -15 -15 -30 -15 0 0 203.9 2.1 
 0 0 0 0 0 10 0  -15 0 0 -30 0 -30 30  -30 -30 -15 -30 -15 -15 15 205 2.1 
 0 0 0 0 0 10 0  0 0 0 -30 0 -15 -15  -30 -30 -15 -30 -15 0 15 206.4 1.7 
 10 10 0 0 0 10 0  15 0 0 0 15 -30 0  0 -15 -15 -15 0 0 0 626.5 1.2 
 6 8 5 -4 -1 11 4  18 2 2 -3 15 -25 3  5 -19 -13 -9 0 1 3 696 1 
 0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0 1032.7 2 
 
The RMSD is the backbone RMSD to the β2-adrenergic receptor crystal structure.  
The structure highlighted in orange is the structure closest to the crystal structure, 
given that the x and y values are from the A2A adenosine template.  The structure 
highlighted in green is the original structure in the incorrect template.  The 
structure highlighted in yellow is the closest structure to the crystal structure 
given the angles sampled.  
 
 For A2A adenosine helices with the x, y, φ, θ and η values of the                  
β2-adrenergic template, SuperBiHelix and SuperComBiHelix causes the RMSD 
to the A2A adenosine receptor crystal structure to go from 2.1 Å to 1.4 Å.  This is 
a good improvement, given that the best RMSD possible, given the angles 
sampled, is 1.2 Å.  These results are shown in Table 14, and the alignments 
between the crystal structure and the structures before and after SuperBiHelix 
and SuperComBiHelix are shown in Figure 20. 
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Figure 19.  Intracellular (left) and extracellular (right) views of the β2-adrenergic 
receptor helices in the A2A adenosine template before (top, green) and after 
(bottom, blue) SuperBiHelix and SuperComBiHelix.  The β2-adrenergic crystal 
structure (orange) is present for comparison. The residues shown are those that 
are important for ligand binding or highly conserved in class A GPCRs.  They are 
N51(1), D79(2), D113(3), W158(4), S204(5), N293(6) and N312(7). 
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Table 14. SuperComBiHelix results for the A2A adenosine receptor with β2-
adrenergic template φ, θ, η, x and y values 
 
θ H1 H2 H3 H4 H5 H6 H7 φ H1 H2 H3 H4 H5 H6 H7 η  H1 H2 H3 H4 H5 H6 H7 
Energy 
(kcal/mol) 
RMSD 
(Å) 
 0 -10 -10 0 0 -10 0  -15 -15 0 30 0 0 0  0 30 15 -30 0 0 0 224.2 1.4 
 0 -10 -10 0 0 -10 0  -30 -30 0 30 0 0 0  0 30 15 -30 0 0 0 235.9 1.7 
 0 -10 -10 0 0 -10 0  -15 -15 0 30 -15 15 0  0 30 15 -30 -15 0 0 238.7 1.4 
 0 -10 -10 0 0 -10 0  -30 -15 0 30 0 0 0  15 30 15 -30 0 0 0 240 1.6 
 0 -10 -10 0 10 -10 0  -30 -15 0 30 15 0 0  15 30 15 -30 30 0 0 241.1 2 
 0 -10 -10 0 0 -10 0  -15 -15 0 30 0 30 0  15 30 15 -30 0 0 0 243.5 1.4 
 0 -10 -10 0 0 -10 0  -15 -15 0 30 0 0 0  15 30 15 -30 0 0 0 243.7 1.4 
 0 -10 -10 0 10 -10 0  -15 -15 0 30 15 -15 0  0 30 15 -30 30 0 0 244.3 1.8 
 0 -10 -10 0 10 -10 0  -15 -15 0 30 15 0 0  0 30 15 -30 30 0 0 245.2 1.8 
 0 -10 -10 0 0 -10 0  -30 -15 0 30 0 0 0  0 30 15 -30 0 0 0 249.4 1.6 
 -6 -8 -5 4 1 -11 -4  -18 -2 -2 3 -15 25 -3  -5 19 13 9 0 -1 -3 280.1 1 
 -10 -10 0 0 0 -10 0  -15 0 0 0 -15 30 0  0 15 15 15 0 0 0 354.7 1.2 
 0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0 849.7 2.1 
 
The RMSD is the backbone RMSD to the A2A adenosine receptor crystal 
structure.  The structure highlighted in orange is the structure closest to the 
crystal structure, given that the x and y values are from the β2-adrenergic 
template.  The structure highlighted in orange is the crystal structure.  The 
structure highlighted in green is the original structure in the incorrect template.  
The structure highlighted in yellow is the closest structure to the crystal structure 
given the angles sampled. 
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Figure 20. Intracellular (left) and extracellular (right) views of the A2A adenosine 
receptor helices in the β2-adrenergic template before (top, green) and after 
(bottom, blue) SuperBiHelix and SuperComBiHelix.  The A2A adenosine crystal 
structure (orange) is present for comparison. The residues shown are those that 
are important for ligand binding or highly conserved in class A GPCRs.  They are 
N24(1), D52(2), L85(3), W129(4), M177(5), N253(6) and I274(7). 
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The Effect of SuperBiHelix on Binding Site Predictions 
Although RMSD is a good metric for testing SuperBiHelix, it does not take ligand 
binding into account.  One of the main purposes of predicting GPCR structures is 
for drug design, so it is important to measure how well ligand binding can be 
predicted in structures predicted by SuperBiHelix.  Thus, carazolol was docked 
into the β2-adrenergic structures before and after SuperBiHelix and 
SuperComBiHelix, and ZM241385 was docked into the A2A adenosine structures 
before and after SuperBiHelix and SuperComBiHelix.  Then these docked results 
were compared to the ligand-bound crystal structures, to see whether 
SuperBiHelix improved docking.  The ligands were also docked into the ligand-
free crystal structure for purposes of comparison. 
 Each structure was prepared for docking by mutating all the bulky, nonpolar 
residues to alanine.  Then a sphere set representing the binding region was 
formed by taking a 2.0 Å radius around the coordinates of the crystal-bound 
ligand. The ligands were assigned Mulliken charges from quantum mechanics 
(B3LYP flavor of DFT using the 6-31G** basis set, calculated with Jaguar).  
GenDock, which is based on Dock6,[49] was used to dock the ligand with the 
DarwinDock method.  DarwinDock generates a large number of poses using 
Dock6, then clusters using Voronoi clustering.  The program then adds 5000 new 
ligand poses (again from Dock6).  If the fraction of new families is less than 1/20, 
then completeness is achieved.  The program then scores the family heads of 
the Voronoi families.  Then, 1/10 of the families are scored completely based on 
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the family head energies.  Finally, the top 100 structures are passed on to the 
next step.  
 For each of these 100 ligand configurations, the bulky nonpolar residues are 
dealanized back to their original form, and all of the side chains in a 4 Å unified 
binding site, defined as all residues within a 4 Å radius of the docked ligand in all 
of the complexes, are reassigned with SCREAM.  The complexes are ranked by 
total energy, and the best 50% are kept for neutralization.  The complexes are 
neutralized, and then ranked by total energy, and the best 50% are kept for 
minimization.  The 4.0 Å unified binding site is minimized for 50 steps.  The 
complexes are ranked by total energy, and the best 50% are kept for the final 
step, resulting in 13 final structures. All of the full complexes are minimized for 
either 500 steps or to a 0.25 kcal/molÅ RMS force threshold.  The final 13 
structures are put through a quench-anneal cycle (50 K to 600 K and back over 
11.5 ps) with the charged forcefield, selecting the configuration with the lowest 
potential energy structure.  Then the structures are reneutralized and 
reminimized. 
 The 13 final docked structures for each structure were all compared to the 
ligand-bound crystal structure.  The similarity to the ligand-bound crystal 
structure was measured with the contact RMSD.  This is calculated by first 
determining the closest contacts for the ligand on each residue for the crystal 
structure, and finding their contact distances.  Then the same contact distances 
are determined for the predicted ligand-bound complex.  Finally, the RMSD is 
calculated between the two sets of distances.   
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 For carazolol docked into the ligand-free β2-adrenergic crystal structure, the 
contact RMSD is 2.4 Å.  For the β2-adrenergic helices in the A2A adenosine 
template before SuperBiHelix, the lowest contact RMSD in the final 13 docked 
structures is 4.5 Å, and after SuperComBiHelix it is 4.4 Å.  These bound 
structures are seen in Figure 21.  Although there is very little improvement in the 
contact RMSD from SuperBiHelix, inspection of the bound structures shows 
marked improvement.  In the crystal structure, carazolol forms strong hydrogen 
bonds with D113(3) and N312(7).  In the structure before SuperBiHelix, carazolol 
only has a hydrogen bond with D113(3).  However, after SuperComBiHelix, 
carazolol makes strong hydrogen bonds with both D113(3) and N312(7).  So, 
SuperBiHelix does make the binding site more like that of the crystal structure.  
 For ZM241385 docked into the ligand-free A2A adenosine crystal structure, 
the contact RMSD is 2.4 Å.  For the A2A adenosine helices in the β2-adrenergic 
template before SuperBiHelix, the lowest contact RMSD in the final 13 docked 
structures is 4.6 Å, and after SuperComBiHelix it is 3.4.  Thus, SuperBiHelix 
makes the binding site much more like that of the crystal structure.  As seen in 
Figure 22, which shows the docked structures, the docked ligand in the best 
energy SuperComBiHelix structure is very similar to the pose in the crystal 
structure.  They both make strong hydrogen bonds with N253(6).  The docked 
ligand in the structure before SuperBiHelix takes a different pose, and does not 
form any hydrogen bond with N253(6).   
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Figure 21. The carazolol-bound β2-adrenergic crystal structure (top), along with 
carazolol docked into the β2-adrenergic helices in the A2A adenosine template 
before SuperBiHelix (middle) and after SuperComBiHelix (bottom). 
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Figure 22. The ZM241385-bound A2A adenosine crystal structure (top), along 
with ZM241385 docked into the A2A adenosine helices in the β2-adrenergic 
template before SuperBiHelix (middle) and after SuperComBiHelix (bottom). 
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While SuperBiHelix improves the binding site predictions for both β2-adrenergic 
helices in the A2A adenosine template and A2A adenosine helices in the            
β2-adrenergic template, it has more effect on the A2A adenosine helices in the 
β2-adrenergic template.  This agrees with the RMSD calculations for 
SuperBiHelix, in which there is a larger effect on the A2A adenosine helices in the 
β2-adrenergic template than the β2-adrenergic helices in the A2A adenosine 
template. 
SuperBiHelix on Crystal Structures 
The SuperBiHelix and SuperComBiHelix procedures were developed by testing 
them on helices from one crystal structure in the template of another crystal 
structure.  It is also important to determine whether performing SuperBiHelix and 
SuperComBiHelix on a crystal structure itself returns the original structure.  
Therefore SuperBiHelix and SuperComBiHelix were run on the A2A adenosine 
receptor and the β2-adrenergic crystal structure, sampling θ with values of −10o, 
0o and 10o, φ with values of −30o, −15o, 0o, 15o and 30o, and η with values of −30o, 
−15o, 0o, 15o and 30o.  The first test was to see how well the quadhelix protocol 
that determines which conformations to include in the SuperBiHelix bundle 
energy calculations worked.  In order for the original crystal structure to show up 
in the best energy SuperBiHelix and SuperComBiHelix structures, the crystal 
conformation for each helix must be in that helix’s top 36 conformations.  The 
ranking of the crystal conformation for each helix for the A2A adenosine receptor 
and the β2-adrenergic receptor is shown in Table 15.   
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Table 15.  The ranking of the crystal structure conformation for each helix after 
the quadhelix protocol that determines which helix conformations to include in the 
SuperBiHelix bundle energy calculations 
 
  
 
Results are for both the A2A adenosine receptor and the β2-adrenergic receptor.  
 
The crystal structure conformation for each helix is indeed in the top 36 helical 
conformations.  In fact, for many helices, the crystal structure is the best 
conformation.  Even the worst ranking for a helix is for TM6 in the β2-adrenergic 
receptor, ranked number 12.  So, the quadhelix protocol works well for the A2A 
adenosine receptor and the β2-adrenergic receptor crystal structures. 
 The next test was to determine whether the ranking of the top 1000 
SuperBiHelix structures is improved by SuperComBiHelix.  The SuperBiHelix and 
SuperComBiHelix results are shown for the β2-adrenergic receptor crystal 
structure in Table 16. In the SuperBiHelix structures, the crystal structure is rank 
78, and after SuperComBiHelix, it is rank 25. Not only does SuperComBiHelix 
cause significant improvement in the rank of the crystal structure, it also slightly 
improves the backbone RMSD values of the 10 structures.  
 
  
 
 
TM β2 A2A 
1 1 1 
2 1 1 
3 1 4 
4 2 7 
5 3 4 
6 12 2 
7 1 1 
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Table 16.  SuperBiHelix and SuperComBiHelix results for the β2-adrenergic 
receptor crystal structure 
 
SuperBiHelix  
θ H1 H2 H3 H4 H5 H6 H7 φ H1 H2 H3 H4 H5 H6 H7 η  H1 H2 H3 H4 H5 H6 H7 
Energy 
(kcal/mol) 
RMSD 
(Å) 
 0 0 0 0 0 0 0  0 0 0 -15 0 -30 -15  0 0 0 0 0 0 0 338.9 0.7 
 0 0 0 0 0 0 0  0 0 0 -15 0 -30 -15  0 0 0 15 0 0 0 341.2 0.7 
 0 0 0 0 0 0 0  0 0 0 -15 0 -15 -30  0 0 0 0 0 0 0 343 0.6 
 0 0 0 0 0 0 0  0 0 0 -15 0 15 0  0 0 0 0 0 0 0 343.3 0.5 
 0 0 0 0 0 0 0  0 0 0 -15 0 -15 -15  0 0 0 0 0 0 0 343.8 0.5 
 0 0 0 0 0 0 0  0 0 0 -15 -15 15 0  0 0 0 0 -15 0 0 344.4 0.6 
 0 0 0 0 0 0 0  0 0 0 -15 0 -15 -30  0 0 0 15 0 0 0 345.4 0.7 
 0 0 0 0 0 0 0  0 0 0 -15 0 15 15  0 0 0 0 0 0 0 345.5 0.5 
 0 0 0 0 0 0 0  0 0 0 -15 0 15 0  0 0 0 15 0 0 0 345.7 0.5 
 0 0 0 0 0 0 0  0 0 0 0 0 -30 -15  0 0 0 15 0 0 0 346.3 0.7 
  0 0 0 0 0 0 0   0 0 0 0 0 0 0   0 0 0 0 0 0 0 357.6 0 
 
 
SuperComBiHelix 
θ H1 H2 H3 H4 H5 H6 H7 φ H1 H2 H3 H4 H5 H6 H7 η  H1 H2 H3 H4 H5 H6 H7 
Energy 
(kcal/mol) 
RMSD 
(Å) 
 0 0 0 0 0 0 0  0 0 0 15 0 0 -15  0 0 0 0 0 0 0 12.7 0.4 
 0 0 0 0 0 0 0  0 0 0 0 0 0 -15  0 0 0 0 0 0 0 13.5 0.4 
 0 0 0 0 0 0 0  0 0 0 -15 0 -15 0  0 0 0 0 0 0 0 18 0.4 
 0 0 0 0 0 0 0  0 0 0 -15 -15 -15 0  0 0 0 0 -15 0 0 25.3 0.6 
 0 0 0 0 0 0 0  0 0 0 -15 -15 0 -15  0 0 0 0 -15 0 0 27.2 0.6 
 0 0 0 0 0 0 0  0 0 0 0 0 -15 0  0 0 0 0 0 0 0 28.9 0.4 
 0 0 0 0 0 0 0  0 0 0 -15 0 0 -15  0 0 0 0 0 0 0 29.3 0.4 
 0 0 0 0 0 0 0  0 0 0 15 -15 15 15  0 0 0 0 -15 0 0 30.6 0.6 
 0 0 0 0 0 0 0  0 0 0 15 0 0 0  0 0 0 0 0 0 0 31.3 0.3 
 0 0 0 0 0 0 0  0 0 0 -15 0 0 15  0 0 0 0 0 0 0 31.3 0.4 
 0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0 46.4 0 
  
The top ten structures for both SuperBiHelix and SuperComBiHelix are shown, 
along the with crystal structure, which is highlighted in orange.  The crystal 
shows up as rank 78 for SuperBiHelix and rank 25 for SuperComBiHelix. 
 
 The SuperBiHelix and SuperComBiHelix results for the A2A adenosine 
receptors crystal structure are in Table 17. The rank of the crystal structure goes 
from 2nd in SuperBiHelix to 6th in SuperComBiHelix.  Although SuperComBiHelix 
makes the crystal structure rank slightly worse than in SuperBiHelix, 
SuperComBiHelix significantly improves the backbone RMSD values of the top 
 90 
ten structures.  Thus, SuperBiHelix and SuperComBiHelix are successful for both 
the β2-adrenergic and A2A adenosine crystal structures. 
 
Table 17.  SuperBiHelix and SuperComBiHelix results for the A2A adenosine 
receptor crystal structure 
 
SuperBiHelix 
θ H1 H2 H3 H4 H5 H6 H7 φ H1 H2 H3 H4 H5 H6 H7 η  H1 H2 H3 H4 H5 H6 H7 
Energy 
(kcal/mol) 
RMSD 
(Å) 
 0 0 0 -10 10 0 0  0 0 15 -30 0 0 0  0 0 0 -30 30 0 0 392.6 1.3 
  0 0 0 0 0 0 0   0 0 0 0 0 0 0   0 0 0 0 0 0 0 396.9 0 
 0 0 0 -10 0 0 0  0 0 15 -30 0 -15 0  0 0 0 -30 -15 0 0 398.3 1 
 0 0 0 -10 10 0 0  0 0 15 -30 0 0 0  0 0 15 -30 30 0 0 400.6 1.3 
 0 0 0 -10 0 0 0  0 0 15 -30 0 0 0  0 0 0 -30 0 0 0 400.7 0.9 
 0 0 0 -10 0 0 0  0 0 15 -30 0 0 0  0 0 0 -30 -15 0 0 401.2 0.9 
 0 0 0 -10 10 0 0  0 0 15 -30 -15 0 0  0 0 0 -30 15 0 0 401.3 1.3 
 0 0 0 0 0 0 0  0 0 0 15 0 0 0  0 0 0 0 0 0 0 402.4 0.4 
 0 0 0 -10 10 0 0  0 -15 15 -30 0 0 0  0 0 0 -30 30 0 0 402.4 1.3 
 0 0 0 -10 0 0 0  0 0 15 -30 -15 0 0  0 0 0 -30 0 0 0 402.8 1 
 
 
SuperComBiHelix 
θ H1 H2 H3 H4 H5 H6 H7 φ H1 H2 H3 H4 H5 H6 H7 η  H1 H2 H3 H4 H5 H6 H7 
Energy 
(kcal/mol) 
RMSD 
(Å) 
 0 0 0 0 0 0 0  0 0 0 0 -15 0 0  0 0 0 0 0 0 0 59.1 0.4 
 0 0 0 0 0 0 0  0 0 -15 0 0 0 0  0 0 0 0 0 0 0 71.2 0.4 
 0 0 0 0 0 0 0  0 0 -15 0 0 15 0  0 0 0 0 0 0 0 74.7 0.6 
 0 0 0 0 0 0 0  0 0 -15 0 0 -15 0  0 0 0 0 0 0 0 76.3 0.7 
 0 0 0 0 0 0 0  0 0 0 -15 0 -15 0  0 0 0 0 0 0 0 77 0.6 
 0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0 78 0 
 0 0 0 0 10 0 0  0 0 0 0 0 -15 0  0 0 0 0 15 0 0 79.1 1 
 0 0 0 0 0 0 0  0 0 0 0 0 -15 0  0 0 0 0 0 0 0 85.8 0.5 
 0 0 0 0 0 0 0  0 0 0 0 0 -15 -15  0 0 0 0 0 0 0 86.2 0.6 
 0 0 0 0 0 0 0  0 0 -15 0 0 15 15  0 0 0 0 0 0 0 87.8 0.6 
 
The top ten structures for both SuperBiHelix and SuperComBiHelix are shown, 
which include the crystal structure, highlighted in orange. 
 
 The SuperComBiHelix results of both the β2-adrenergic and A2A adenosine 
crystal structures show that there is the most variation in the sweep angles of the 
helices.  Neither receptor shows any variation in TM1 and TM2.   The sweep 
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angle of TM3 differs from the crystal structure in the A2A adenosine receptor, but 
not in the β2-adrenergic receptor.  The sweep angles of TM4, TM5, TM6 and 
TM7 vary for both receptors.  Finally, TM5 is the only helix whose η value 
changes from the crystal structure, for both receptors.  Thus, it seems that TM5 
is most flexible in both receptor.   
 It must be taken into account that the ligand is not present during the 
SuperBiHelix and SuperComBiHelix procedures.  The crystal structures are 
determined with the ligand bound, so the ligand-free crystal structure may still not 
be the lowest energy structure.  The presence of the ligand would change the 
order of the structures.  Additionally, the presence of the loops may change the 
ordering of the structures.  However, even taking these factors into account, the 
SuperBiHelix procedure is a very promising method for the prediction of new 
GPCR structures.  
 
Conclusion 
 SuperBiHelix and SuperComBiHelix allow for the efficient sampling of GPCR 
conformational space.  This makes it possible to predict structures of receptors 
that are dissimilar to any experimental crystal structure.  It also predicts an 
ensemble of low-lying structures, mirroring the flexibility of GPCR structures.  
When helices from one crystal structure are placed into the template of another 
structure, SuperBiHelix and SuperComBiHelix successfully move the 
experimental helices closer to their original template.  The procedure also 
improves binding site predictions and makes ligand binding calculations more 
 92 
accurate.  The success of SuperBiHelix and SuperComBiHelix on experimental 
crystal structures will now lead to better predictions of GPCR structures and 
binding sites, and therefore more successful rational drug design.  
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Chapter 3 
 
The Structure of the Orphan G Protein-Coupled 
Receptor GPR88 with Predicted Ligands 
 
 
Abstract 
GPR88 is an orphan GPCR, with no known ligands that bind to it.  It has been 
identified as a novel target for psychiatric disorders.  In order to determine which 
types of ligands that could bind to it, three low energy structures were predicted 
for GPR88.  Based on inspection of the structures, lipids were predicted to bind 
to GPR88. The head group of a lipid would bind to R113(3) and R116(3) at the 
extracellular side of the receptor.  The lipid tail would bind in an aliphatic pocket 
in the TM2-TM3-TM6-TM7 region. Three lipids were docked to the predicted 
GPR88 structures: S1P, LPA and FFA.  The predicted bound structures show 
that all three lipids would likely bind to GPR88, with the head group forming 
hydrogen bonds to R113(3) and R116(3).  The residues contributing favorably to 
the binding of the lipid tails would be L120(3), L124(3), W84(2), W322(7), 
C325(7), L305(6), S321(7), L328(7), V301(6), and S127(3), in order of 
decreasing predicted strength of interaction.  The predicted bound complexes 
offer good suggestions for binding and mutagenesis experiments that could help 
validate the predicted structures. 
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Introduction 
A GPCR for which the endogenous ligand is unknown is called an orphan 
receptor.  One such orphan receptor that was discovered in 2000 is the GPCR 
GPR88.[50] In fact, not only is the endogenous ligand unknown for GPR88, no 
ligand is known to bind the GPR88.  Additionally, its function is unknown.  It is 
found in both human and rodent striatum,[50, 51] which implies that its function may 
be psychiatric.  Supporting this is the fact that schizophrenia-like phenotypes are 
displayed by GPR88 knock-out mouse.[52] In addition, antidepressant treatments 
affect levels of GPR88 expression.[53] Finally, GPR88 has identified as a novel 
target for movement disorders as well as psychiatric disorders.[54]  
 The primary sequence of GPR88 shows the highest homology to biogenic 
amine receptors.  However, some highly conserved residues in biogenic amine 
receptors, including the aspartic acid in TM3 that makes a salt bridge with the 
protonated amine of biogenic amine ligands, are not present in GPR88.  This 
implies that GPR88 may represent a novel subtype of GPCR.[50] A model 3D 
structure of GPR88 could help to determine the type of ligands that will bind to 
GPR88, and perhaps even help classify the receptor.  However, the lack of any 
experimental structural, ligand binding or mutation data will make any predictions 
difficult to verify even indirectly.  Hopefully, predictions will lead to direct binding 
and mutation experiments with GPR88 that could lead rational drug design for 
GPR88. 
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Methodology 
The Membstruk methodology for determining the serotonin receptors in Chapter 
1 gave reasonable structures, but it was fairly ad hoc and it required knowledge 
of the system, including important residues in the system for binding and 
stabilization. This method would not work for GPR88 because there is no 
experimental knowledge of its structure or binding.  Instead, the SuperBiHelix 
method described in Chapter 2 was used.  The starting structure for SuperBiHelix 
was the best structure from the BiHelix procedure. 
 In order to use the BiHelix procedure, the helices must first be predicted   
that will be put into each experimental template.  A new procedure, PredicTM, 
was developed in the group to predict the TM helices of the protein.  In this 
procedure, like the old TM prediction method, sequences are found with BLAST 
that are related to the target sequence.  For GPR88, BLAST was run to get 
structures up to an e-value of 0.2, which gave 290 structures. The top 20 
structures closest to human GPR88 are shown in Table 18.  Then MAFFT[55] is 
used to align these sequences, and any segments of the alignment 
corresponding to gaps in the target sequence are removed.  The White octanol 
hydrophobicity scale[56], which is a thermodynamic scale based on the 
partitioning of amino acids from water to octanol, is used to assign a 
hydrophobicity value to each amino acid in the alignment.  These values are then 
averaged over windows of residue length 7−21, then averaged over these 
averages to decrease the noise in the hydrophobic profile.  The hydrophobic 
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profile for GPR88, in which seven hydrophobic peaks that represent the seven 
TM helices, is shown in Figure 23. 
 
Table 18.  Proteins sequentially related to GPR88 
 
Accession E-value % Identity Receptor 
Q9GZN0 0 100 GPR88 human 
Q9EPB7  0 95 GPR88 mouse 
Q9ESP4  0 94 GPR88 rat 
P25962  2.564e-14  23 Beta-3 adrenergic mouse 
P79148  6.3153e-13  21 Beta-1 adrenergic dog 
Q9TT96  2.3998e-12  20 Beta-1 adrenergic bovine 
P13945  5.3462e-12  22 Beta-3 adrenergic human 
P28221  5.3462e-12  19 5-HT1D human 
Q9TST6  6.9824e-12  21 Beta-1 adrenergic cat 
O02666  9.1193e-12  22 Alpha-1D adrenergic rabbit 
Q28524  1.191e-11  21 Beta-3 adrenergic rhesus 
P08588  1.191e-11  19 Beta-1 adrenergic human 
P23944  1.191e-11  19 Alpha-1D adrenergic rat 
Q28927  1.5555e-11  19 Beta-1 adrenergic sheep 
O02662  2.0316e-11  23 Beta-3 adrenergic dog 
Q95252  2.6533e-11  21 Beta-3 adrenergic pig 
P97714  4.5259e-11  19 Alpha-1D adrenergic mouse 
P34971  1.0083e-10  20 Beta-1 adrenergic mouse 
P47899  2.2462e-10  19 Beta-1 rhesus 
Q7TQP2  3.8314e-10  19 GP135 mouse 
 
The top 20 sequences were found by BLAST, ordered by increasing e-value. 
 
The hydrophobic profile does a good job of predicting the transmembrane 
regions of the seven helices.  However, GPCR crystal structures show that these 
helices often extend past the hydrophobic membrane region of the lipid bilayer.  
The hydrophobic profile cannot detect this helix extension, but secondary 
structure prediction can.  Thus, secondary structure prediction can be used in 
conjunction with the hydrophobic profile.  The secondary structure servers 
Porter[57] and APSSP2[58] were used to do the predictions.  The secondary 
structures along with the raw predictions are shown in Table 19. 
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Figure 23.  The hydrophobic profile for human GPR88, based on a MAFFT 
alignment of related sequences, with the seven peaks representing the 
transmembrane helices.  The hydrophobicity scale is thermodynamic, so the 
cutoff for the TM part of the helices is a hydrophobicity value 0. 
 
The entire sequence of GPR88 was inputted into the secondary structure servers 
to see the length of the transmembrane helix predictions.  The longer of the two 
secondary structure predictions was taken as the final prediction for each helix, 
except for TM7.  In TM7, the Porter predict predicts TM7 to extend out toward the 
C-terminus, but examination of the hydrophobic profile reveals that the extension 
is probably the eighth helix, which exists in some GPCRs and runs parallel to the 
membrane. 
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Table 19.  TM helix predictions for human GPR88 
 
TM  Predicted TM Region Prediction Method 
1     RIPVSLLYSGLAIGGTLANGMVIY 
       VSLLYSGLAIGGTL 
WAGRRIPVSLLYSGLAIGGTLANGMVIYLVSS 
WAGRRIPVSLLYSGLAIGGTLANGMVIYLVSS  
Raw 
Porter 
APSSP2 
Final Prediction 
2   NAFIVNGCAADLSVCALWMPQEAVLG 
           AADLSVCALWMPQEAVL 
TSNAFIVNGCAADLSVCALWMPQEAVLGLL 
TSNAFIVNGCAADLSVCALWMPQEAVLGLL 
Raw 
Porter 
APSSP2 
Final Prediction 
3         GLLGLGLTVSLLSHCL 
              LTVSLLSHCLVALNRYLLI 
GSYRLLRGGLLGLGLTVSLLSHCLVALNRYLL 
GSYRLLRGGLLGLGLTVSLLSHCLVALNRYLLI 
Raw 
Porter 
APSSP2 
Final Prediction 
4               MLALSWALALGLVLLLP 
ATYQALYQRRHTAGMLALSWALALGLVLL 
        RRHTAGMLALSWALALGLVLLLP 
ATYQALYQRRHTAGMLALSWALALGLVLLLP 
Raw 
Porter 
APSSP2 
Final Prediction 
5  PALLAAAALLAQTALLLHCYLG 
YPALLAAAALLAQTALLLHCYLGIVRR 
  ALLAAAALLAQTALLLHCYLGIVRRVRVSVKR 
YPALLAAAALLAQTALLLHCYLGIVRRVRVSVKR 
Raw 
Porter 
APSSP2 
Final Prediction 
6               LLLCCVFLLATQPLVWVSLAS 
 PRRAQRRLSGLSVLLLCCVFLLA 
HPRRAQRRLSGLSVLLLCCVFLLATQPLVWVSLASGF 
HPRRAQRRLSGLSVLLLCCVFLLATQPLVWVSLASGF 
Raw 
Porter 
APSSP2 
Final Prediction 
7  VHAASWLLCCALSALNPLLY 
GVHAASWLLCCALSALNPLLYTWRNEEFRRSVRSV 
GVHAASWLLCCALSALNPLLYTW 
GVHAASWLLCCALSALNPLLYTW 
Raw 
Porter 
APSSP2 
Final Prediction 
 
The raw predictions are from the hydrophobic profile.  The final predictions take 
the longer of the two secondary structure predictions, except for TM7, in which 
the longer prediction also includes TM8. 
 
 With the residues making up each TM helix having been predicted, the helix 
shapes are then predicted.  Methods have been developed to perform molecular 
dynamics on canonical helices in order to predict the kinks and bends caused by 
helix breakers like proline.  However, these methods do not work in the BiHelix 
procedure as well as using homology helices.  Homology helices are obtained by 
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using one of the available GPCR crystal structures: the β1-adrenergic receptor,[4] 
β2-adrenergic receptor,[5] A2A adenosine receptor,[6] or rhodopsin.[59] The target 
protein is aligned with each of these receptors, and then the residues in the 
crystal helices are mutated to the corresponding residues of the target.  The 
helices are allowed to minimize to accommodate the new side chains.  If the 
predicted helices for the target protein are longer that the crystal helices, then the 
crystal helix lengths are used. 
 Each set of homology helices based on an experimental crystal structure is 
then placed in its respective templates.  When using homology helices, the 
hydrophobic centers of the helices are those of the corresponding experimental 
helices, as defined by the OPM database.[60] The hydrophobic centers are 
aligned along the z-axis, while the template defines the x and y values in the 
plane as well as the tilt and sweep angles, θ and φ.  In order to optimize the 
rotation of each helix on its own axis, BiHelix and ComBiHelix are run for each 
set of homology helices in their respective templates.  Then the template that 
gives the lowest ComBiHelix energy is used for SuperBiHelix and 
SuperComBiHelix.  
 
Results and Discussion 
BiHelix and ComBiHelix 
After running ComBiHelix for GPR88 in the available crystal templates, the β2-
adrenergic receptor template and homology helices gave the lowest energy for 
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GPR88.  The ComBiHelix results for the top 10 structures of GPR88 in the β2-
adrenergic receptor template are given in Table 20. 
 
Table 20.  ComBiHelix results for GPR88 in the β2-adrenergic receptor template 
 
H1 H2 H3 H4 H5 H6 H7 
Energy 
(kcal/mol) 
0 0 0 180 0 90 60 -376.7 
0 0 0 180 0 60 60 -373.4 
0 0 0 0 30 60 60 -371.5 
0 0 0 0 0 90 60 -370.8 
0 0 0 0 0 60 60 -369.0 
0 0 0 210 0 90 60 -367.2 
0 0 0 120 30 60 60 -367.1 
0 0 0 150 30 60 60 -366.8 
0 0 0 210 0 60 60 -365.5 
0 0 0 120 0 60 60 -360.9 
 
The zeros represent the same rotation for the helix as in the β2-adrenergic 
receptor crystal structure.  TM4 and TM5 are the most flexible rotationwise, while 
TM1, TM2, TM3 and TM7 are fixed. 
 
The ComBiHelix results show that TM1, TM2 and TM3 have the same rotations 
as the β2-adrenergic receptor.  TM7 is rotated 60o clockwise from the β2-
adrenergic receptor, but is fixed in that position.  TM6 prefers either a rotation of 
60o  or 90o from the β2-adrenergic receptor.  TM4 and TM5 are the most flexible 
rotationwise.  Interestingly, the ComBiHelix results of the β2-adrenergic receptor 
itself show that TM1, TM4 and TM5 are the most flexible rotationwise.  Thus, it is 
not surprising that TM4 and TM5 are also flexible in GPR88.  Additionally, among 
the proteins included in the BLAST search to create the hydrophobic profile for 
GPR88, TM5 has the least similarity to the other proteins in the alignment. 
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 The lowest energy structure from the ComBiHelix procedure for GPR88 is 
shown in Figure 24.  The predicted structure seems quite stable in that there are 
several strong interhelical hydrogen bonds.  TM2 and TM3 are strongly coupled 
by a salt bridge near the extracellular side between R116(3) and E88(2) in 
addition to a strong hydrogen bond between R113(3) and Q87(2).  The TM1-
TM2-TM7 hydrogen bonding network present in class A GPCRs is found in the 
GPR88 structure, with hydrogen bonds between N49(1), D77(2) and N332(7). 
There is a hydrogen bonding network between the intracellular sides of TM2, 
TM3 and TM4, connecting T65(2), N137(3) and R156(4).  However, the residues 
involved in that network are very near the termini of their helices, so they may 
interact with the head groups of the lipid bilayer instead of each other. Finally, 
there is a weak hydrogen bond between T205(3) and Q298(6).  Given that the 
strongest hydrogen bonding networks involve TM1, TM2, TM3 and TM7, it is not 
surprising that the ComBiHelix analysis shows that those helices are nonflexible 
rotationwise, in order to preserve the hydrogen bonding networks. 
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Figure 24.  The lowest energy structure from ComBiHelix analysis on GPR88, in 
the β2-adrenergic receptor template.  The top is the extracellular view and the 
bottom the intracellular view.  The residues shown are those involved in 
interhelical hydrogen bonding, with the dotted lines showing hydrogen bonds.   
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SuperBiHelix and SuperComBiHelix 
 SuperBiHelix and SuperComBiHelix were run on the best BiHelix structure of 
GPR88 in the β2-adrenergic receptor template.  The angles sampled were −10o, 
0o and 10o for the tilt angle, θ; −30o, −15o, 0o, 15o and 30o for the sweep angle, φ; 
and −30o, −15o, 0o, 15o and 30o for the rotation around the helical axis, η.  These 
angles were chosen because an examination of experimental crystal structure 
templates shows that the templates do not vary by much more than these values.  
Additionally, it is assumed that the starting structure, the lowest energy BiHelix 
structure, is somewhat close to the global lowest energy structure.  The results 
from SuperBiHelix and SuperComBiHelix are shown in Table 21. 
 
 
Table 21.  SuperComBiHelix results for GPR88 
  
θ H1 H2 H3 H4 H5 H6 H7 φ H1 H2 H3 H4 H5 H6 H7 η H1 H2 H3 H4 H5 H6 H7 
Energy 
(kcal/mol) 
 -10 0 0 0 10 10 10  -30 15 15 15 15 -30 0  15 -15 0 -15 -15 0 0 -468.8 
 0 0 -10 0 10 0 0  -15 -15 15 30 0 -30 15  15 0 -15 -15 -15 0 15 -466.4 
 0 0 -10 0 10 0 0  -15 -15 15 30 0 -15 15  15 0 -15 -15 -15 0 15 -465 
 0 0 -10 0 10 0 0  -15 -15 15 15 0 -15 15  15 0 -15 -15 -15 0 15 -462.6 
 -10 0 0 0 10 10 10  -30 15 15 -30 15 -30 0  15 -15 0 30 -15 0 0 -459.2 
 -10 0 -10 10 -10 0 10  -15 -15 -15 0 15 0 30  0 -30 15 -15 -30 30 -30 -457.4 
 0 0 -10 10 10 0 0  -15 -15 30 -30 0 -15 15  0 30 0 -15 -30 -30 -30 -454.2 
 0 0 -10 0 10 0 0  -15 -15 15 15 0 -30 15  15 0 -15 -15 -15 0 15 -453.5 
 -10 0 0 0 10 10 10  -30 15 15 0 15 -30 0  15 -15 0 0 -15 0 0 -450.5 
 -10 0 0 0 10 10 10  -30 15 15 -15 15 -30 0  15 -15 0 0 -15 0 0 -450 
   
The starting structure for the SuperBiHelix and SuperComBiHelix procedure, 
which would be 0o for all angles, is the lowest energy structure from BiHelix in the 
β2-adrenergic receptor template. 
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 The original structure, the lowest energy structure from ComBiHelix, does not 
show up in the 2000 best structures from SuperBiHelix.  However, its energy      
(−461.3 kcal/mol) actually makes it the fifth lowest energy of the 
SuperComBiHelix structures.  This is due to the fact that procedure that 
determines the best SuperBiHelix structures based on the energies of the TM1-
TM2-TM3-TM7, TM2-TM3-TM4-TM5 and TM3-TM5-TM6-TM7 quadehelix 
bundles can overlook good energy structures.  Thus, the original ComBiHelix 
structure was kept for further analysis and docking.  An inspection of the 
SuperComBiHelix results shows that the sweep angles show the most variation, 
especially in TM4.  The lowest energy structure, shown in Figure 25, was kept for 
docking and further analysis.  The next three structures by energy only differ by 
15o in the sweep angles of TM4 and TM6, so they are probably important 
structures.  Thus, the second lowest energy structure, shown in Figure 26, was 
also kept for docking and further analysis.   
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Figure 25.  The lowest energy structure from SuperComBiHelix analysis on 
GPR88.  The top is the extracellular view and the bottom the intracellular view.  
The residues shown are those involved in interhelical hydrogen bonding, or those 
that were in the BiHelix structure, with the dotted lines showing hydrogen bonds.   
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Figure 26.  The second-lowest energy structure from SuperComBiHelix analysis 
on GPR88.  The top is the extracellular view and the bottom the intracellular view.  
The residues shown are those involved in interhelical hydrogen bonding, or those 
that were in the BiHelix structures, with the dotted lines showing hydrogen bonds.   
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 The two lowest energy structures from SuperComBiHelix have similar 
hydrogen bonding networks to the BiHelix structure.  
• The lowest energy structure has a salt bridge between R113(3) and 
E88(2).  However, there are no hydrogen bonds involving R116(3) or 
Q87(2).  On the second-lowest energy structure, R116(3) is making a salt 
bridge with E88(2) and forming a hydrogen bond with Q87(2).  Q87(2) is 
also in a hydrogen bond with Y112(3).  R116(3) is not involved in any 
hydrogen bonding in the second-lowest energy structure.   
• Both SuperComBiHelix structures have a hydrogen bond between T205(5) 
and Q298(6). 
• Like the BiHelix structure, both structures have a hydrogen bond between 
R156(4) and N137(3).  There is no interaction with T65(2) like in the 
BiHelix structure.  The second-lowest energy structure does have a 
hydrogen bond between S66(2) and N137(3). 
• The lowest energy structure does not have the TM1-TM2-TM7 hydrogen 
bonding network.  Instead, D77(2) is making a hydrogen bond with 
S103(3).  N49(1) and N332(7) are not involved in any interhelical 
hydrogen bonding.  In the second-lowest energy structure, D77(2) is in a 
hydrogen bond with N337(2).  Additionally, N49(1) is forming a hydrogen 
bond with Y336(7). 
Based on interhelical hydrogen bonding, the second lowest energy ComBiHelix 
structure seems to be more stable than the lowest energy structure.  Additionally, 
the fact that the second-, third- and fourth-lowest energy structures are almost 
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identical points to the fact that the structure is very important.  However, the 
lowest energy structure was also kept for docking because it does have the best 
energy.  
Ligand Docking 
The docking of ligands to GPR88 is difficult because there are no known ligands 
that bind to the receptor.  Based on a visual inspection of the three predicted 
structures of GPR88, there is an open, aliphatic binding pocket running vertically 
in the TM3-TM6-TM7-TM7 region.  It looks like a lipid could dock in GPR88 with 
a negatively charged head group forming a salt bridge with either R113 or R116 
on TM3 and the aliphatic tail running down into the aliphatic binding pocket.  
Three lipids that commonly bind to GPCRs were docked: lysophosphatidic acid 
(LPA), sphingosene-1-phosphate (S1P) and a free fatty acid (FFA).  These lipids 
are shown in Figure 27. The ligands were built and minimized using the Dreiding 
force field with Mulliken charges from quantum mechanics (B3LYP flavor of DFT 
using the 6-31G** basis set, calculated with Jaguar).  The carboxylic acid head 
group of FFA was given a −1 charge, and one hydrogen was added in the 
neutralization step.  The phosphoric acid head group of LPA and S1P will have a 
-2 charge at biological pH.  However, in the docking algorithm, a −2 charge could 
lead to artificially large long-distance Coulombic interactions.  Thus, a −1 charge 
was given to the phosphoric acid head group, treating each of the three oxygens 
alike. In S1P, the nitrogen was protonated.  In the neutralization step, one 
hydrogen was added to the −1 charged phosphate group to make it neutral in 
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LPA and S1P, and one hydrogen was taken away from the protonated nitrogen in 
S1P. 
   
 
  
Figure 27.  The three lipid molecules that were docked into GPR88. 
 
 Given the large number of rotatable bonds in a lipid, it would be very difficult 
to directly dock the entire lipid in the protein.  Instead, just the head of each lipid 
was docked. First, all of the bulky nonpolar residues (tryptophan, tyrosine, 
phenyalanine, valine, isoleucine and leucine) were mutated to alanine in order to 
allow the ligand to find the best conformation.  Then, a sphere region around 
R113 and R116 on TM3 was created as the binding region for the lipid head 
groups.  GenDock, an in-group docking program based on Dock6[49], was then 
 110 
used to dock the ligand (or head group in this case) with the DarwinDock method. 
DarwinDock generates a large number of poses using Dock6, then clusters using 
Voronoi clustering.  The program then adds 5000 new ligand poses (again from 
Dock6).  If the fraction of new families is less than 1/20, then completeness is 
achieved.  The program then scores the family heads of the Voronoi families.  
Then, 1/10 of the families are scored completely based on the family head 
energies.  Finally, the top 100 structures are passed on to the next step.  
For each of these 100 ligand configurations, the bulky nonpolar residues are 
dealanized back to their original form, and all of the side chains in a 4 Å unified 
binding site, defined as all residues within a 4 Å radius of the docked ligand in all 
of the complexes, are reassigned with SCREAM.  The complexes are ranked by 
total energy, and the best 50% are kept for neutralization.  The complexes are 
neutralized, and then ranked by total energy, and the best 50% are kept for 
minimization.  The 4.0 Å unified binding site is minimized for 50 steps.  The 
complexes are ranked by total energy, and the best 50% are kept for the final 
step, resulting in 13 final structures. All of the full complexes are minimized for 
either 500 steps or to a 0.25 kcal/molÅ RMS force threshold.    
From the top structures, three structures were inspected: the structure with 
the best total complex energy, the structure with the best unified cavity energy, 
and the structure with the best ligand interaction energy.  The best head group 
position was selected from these three structures as the one with the best 
contacts between the functional groups of the ligand and the residues in the 
binding site.   This entire procedure was carried out for the head groups of LPA, 
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S1P and FFA in the three GPR88 predicted structures, resulting in nine 
complexes.  Then, for each structure, the lipid’s tail group was manually placed 
vertically in the TM3-TM6-TM7-TM2 binding site.  Then the tail group and all 
residues within a 4.0 Å radius, except the head group which was kept frozen, 
were minimized and then put through a quench-anneal cycle (50 K to 600 K and 
back over 11.5 ps), selecting the configuration with the lowest potential energy 
structure.  The quench-anneal cycle was carried out with the charged force field.  
Next, the head and tail group were connected, minimized, and the entire lipid and 
residues within a 4.0 Å radius were put through a quench-anneal cycle.  Finally, 
the complex was neutralized, and the binding site, then the entire complex, was 
minimized.  The neutralized binding energies for the three lipids in the three 
GPR88 predicted structures are given in Table 22.  The binding energy is 
calculated as described in Chapter 1. 
 
Table 22.  Neutralized binding energies for three lipids in GPR88 
 
 BiHelix_1 SuperBiHelix_1 SuperBiHelix_2 
LPA -63 kcal/mol -35 kcal/mol -61 kcal/mol 
S1P -55 kcal/mol -51 kcal/mol -68 kcal/mol 
FFA -58 kcal/mol -52 kcal/mol -52 kcal/mol 
 
The binding energies were calculated for three GPR88 predicted structures: the 
best energy ComBiHelix structure (BiHelix_1), the best energy SuperComBiHelix 
structure (SuperBiHelix_1), and the second-best energy SuperComBiHelix 
structure (SuperBiHelix_2). 
 
 The binding energy calculations show there are similar binding energies for 
all of the complexes, except for LPA bound in the best energy SuperComBiHelix 
structure.  An analysis of the interactions between the lipid and specific residues 
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in the binding pocket, shown in Table 23, should give further insight into why this 
complex has a lower binding energy than the others.  Given that the docking 
method for the lipids was very crude, and the binding energies for the three lipids 
are fairly similar, the binding energies probably do not reveal which lipid binds the 
most weakly or strongly.  The predicted bound structures for FFA are in Figure 
28, the predicted bound structures for LPA are in Figure 29, and the predicted 
bound structures for S1P are in Figure 30. 
 Inspection of the bound structures in Figure 28 and the cavity analysis in 
Table 23 shows many important features of FFA binding to GPR88. 
• For FFA binding, the carboxylic head group forms hydrogen bonds and 
has strong Coulombic interactions with R113(3) and R113(6) in all three 
predicted structures.  There are also strong van der Waals interactions in 
all three predicted structures between FFA and W84(2), W322(7) and 
S321(7). 
• In the two SuperComBiHelix structures, there are good van der Waals 
interactions between FFA and L124(3), C325(7) and L120(3). 
• Both the lowest energy ComBiHelix structure and the second lowest 
energy SuperComBiHelix structures have  good van der Waals 
interactions between FFA and L305(6) and V301(6).   
• E88(2) has good interactions with the FFA in best ComBiHelix structure, 
and moderate interactions with FFA in the SuperComBiHelix structures. 
• Only the second best SuperComBiHelix structure has good interactions 
between FFA and S127(3). 
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Thus, based on the three predicted structures for GPR88 bound to FFA, the 
carboxylic acid head group will bind strongly to R113(3) and R116(3), and the tail 
will have strong van der Waals interactions with W84(2), W322(7) and S321(7).  
Additionally, there will be possible good van der Waals interactions with L120(3), 
L124(3), V301(6), L305(6), C325(7), S127(3) and L328(7). 
 
 
Table 23.  Nonbond interaction energies (kcal/mol) between each ligand and 
individual residues within 5.0 Å of the ligand 
 
Residue TM 
BiHelix1 
FFA 
Super1 
FFA 
Super2 
FFA 
BiHelix1 
LPA 
Super1 
LPA 
Super2 
LPA 
BiHelix1 
S1P 
Super1 
S1P 
Super2 
S1P 
Mean 
Energy 
R113 3 -2.2 -3.5 -2.7 -2.7 -6.5 -6.7 -6.7 -7.6 -4.4 -4.8 
R116 3 -4.5 -3.5 -2.7 -8.7 -1.0 -2.3 -3.7 -0.9 0.2 -3.0 
L120 3 -2.5 -1.9 -0.8 -2.9 -3.7 -2.5 -0.9 -3.7 -2.5 -2.4 
L124 3 -0.3 -2.4 -1.9 -3.1 -3.4 -2.3 -2.0 -2.7 -2.2 -2.2 
W84 2 -3.3 -1.9 -2.7 -0.7 -0.7 -2.1 -2.6 -0.3 -3.1 -1.9 
W322 7 -1.4 -1.9 -2.1 -0.5 -1.4 -4.5 -1.8 -4.2 0.8 -1.9 
C325 7 -0.7 -1.9 -1.7 -2.3 -1.8 -0.8 -0.9 -2.2 -2.3 -1.6 
L305 6 -1.3 -0.3 -1.8 -2.7 0.0 -3.3 -1.1 0.0 -2.7 -1.5 
S321 7 -1.3 -1.5 -1.2 -1.3 0.0 -1.5 -1.0 0.0 -5.3 -1.5 
L328 7 -0.6 -1.5 -1.4 -2.4 1.0 -0.3 -1.7 -1.7 -2.4 -1.2 
E88 2 -1.5 -0.6 -0.9 -0.3 -1.4 -0.3 -0.6 -3.3 -1.0 -1.1 
V301 6 -1.4 -0.9 -1.3 0.4 0.0 -2.2 -1.0 0.0 -0.8 -0.8 
S127 3 0.1 0.1 -1.3 -0.9 -1.3 0.6 -0.9 -1.3 -2.0 -0.8 
S304 6 0.0 0.0 -0.8 0.0 0.0 -2.2 0.0 0.0 -0.1 -0.3 
 
The energies were calculated for three GPR88 predicted structures: the best 
energy ComBiHelix structure (BiHelix1), the best energy SuperComBiHelix 
structure (Super1), and the second-best energy SuperComBiHelix structure 
(Super2).  The residues listed are those that have more than 2 kcal/mol of 
favorable energy with at least one ligand.  Those residues that are more that 5.0 
Å from the ligand in the respective structure are given 0.0 kcal/mol interaction 
energy. 
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Figure 28.  Extracellular (left) and side (right) views of the predicted bound 
structure of FFA in the lowest energy ComBiHelix structure (top), the lowest 
energy SuperComBiHelix structure (middle), and the second-lowest energy 
SuperComBiHelix structure (bottom).  The dotted lines represent hydrogen bonds 
to the labeled residues. 
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Figure 29. Extracellular (left) and side (right) views of the predicted bound 
structure of LPA in the lowest energy ComBiHelix structure (top), the lowest 
energy SuperComBiHelix structure (middle), and the second-lowest energy 
SuperComBiHelix structure (bottom).  The dotted lines represent hydrogen bonds 
to the labeled residues. 
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Figure 30. Extracellular (left) and side (right) views of the predicted bound 
structure of S1P in the lowest energy ComBiHelix structure (top), the lowest 
energy SuperComBiHelix structure (middle), and the second-lowest energy 
SuperComBiHelix structure (bottom).  The dotted lines represent hydrogen bonds 
to the labeled residues. 
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 Inspection of the bound structures in Figure 29 and the cavity analysis in 
Table 23 shows many important features of LPA binding to GPR88. 
• The LPA head group forms a hydrogen bond with R113(3) in all the 
predicted structures.  The head group also forms a hydrogen bond with 
R116(3) in the lowest energy ComBiHelix structure and the second lowest 
energy SuperComBiHelix structure.  However, the lowest energy 
SuperComBiHelix structure does not have strong interaction with R116(3), 
which in part explains its low LPA binding energy. 
• All three predicted structures have strong van der Waals interactions with 
L120(3) and L124(3). 
• The carbonyl group of LPA forms a hydrogen bond with the W322(7) in 
the second best SuperComBiHelix structure, but not in the other two 
structures. 
• The best energy ComBiHelix structure and the second best 
SuperComBiHelix structure have very good van der Waals interactions 
with L305(6) and S321(7).  Those residues in the best SuperComBiHelix 
structure are not even within 5 Å of the ligand, contributing to the low 
binding energy of LPA in this structure. 
• The second-lowest energy SuperComBiHelix has good van der Waals 
interactions with W84(2), V301(6) and S304(6). 
• The lowest energy ComBiHelix and SuperComBiHelix structures have 
good van der Waals interactions with C325(7). 
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• The lowest energy ComBiHelix structure has good van der Waals 
interactions with L328(7). 
Based on the three predicted structures of LPA bound to GPR88, the phosphate 
head group will bind strongly to R113(3) and R116(3), and the tail will have 
strong van der Waals interactions with L120(3) and L124(3).  The carbonyl group 
may form a hydrogen bond to W322(7).  There will be possible good van der 
Waals interactions with L305(6), L321(7), C325(7), W84(2), V301(6), S304(6) 
and L328(7).   
 Inspection of the bound structures in Figure 30 and the cavity analysis in 
Table 23 shows many important features of S1P binding to GPR88: 
• All three structures show strong hydrogen bonds between the phosphate 
head group of S1P and R113(3).  The head group does not form hydrogen 
bonds to R116(3) as seen in with the other two lipids.  However, the 
lowest energy ComBiHelix structure does have good van der Waals 
interactions with R116(3). 
• All three structures show hydrogen bonds between the protonated 
nitrogen group of S1P and E88(2).  However, there are unfavorable van 
der Waals interactions that make it so the overall interaction energy is 
moderately favorable.  The lowest energy SuperComBiHelix structure also 
has a hydrogen bond between E88(2) and the hydroxy group of S1P.  
• The second best SuperComBiHelix structure forms a very strong 
hydrogen bond between the hydroxy group on S1P and S321(7).   
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• All three predicted structures have good van der Waals interactions 
between S1P and L124(3) and L328(7). 
• The best two SuperComBiHelix structures have good van der Waals 
interactions between S1P and L120(3), C325(7) and S127(3). 
• There are good van der Waals interactions between W84(2) and L305(6) 
and the S1P in the lowest energy ComBiHelix structure and second lowest 
energy SuperComBiHelix structure. 
• W322(7) has good van der Waals interactions with S1P in the lowest 
energy ComBiHelix structure and the lowest energy SuperComBiHelix 
structure. 
Based on the three predicted structures of S1P bound to GPR88, the phosphate 
head group will bind strongly to R113(3), with the protonated nitrogen group 
forming a hydrogen bond with E88(2).  The tail will have strong van der Waals 
interactions with L328(7) and L124(3).  The hydroxy group on S1P may form a 
hydrogen bond with either S321(7) or E88(2). Additionally, there will be possible 
good van der Waals interactions with L120(3), C325(7), S127(3), W84(2), 
L305(6) and W322(7). 
 In summary, the docking of the LPA, S1P and FFA to the three predicted 
GPCR structures leads to the prediction that GPR88 will bind lipids.  The 
negatively charged head group will bind to R113(3) and R116(3).  In S1P, the 
protonated nitrogen group will form a hydrogen bond with E88(2).  S1P may form 
a hydrogen bond between its hydroxy group and S321(7).  LPA may form a 
hydrogen bond between its carbonyl group and W322(7).  For all three lipids, the 
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important der Waals interactions, in order of increasing strength, are predicted to 
be L120(3), L124(3), W84(2), W322(7), C325(7), L305(6), S321(7), L328(7), 
V301(6), and S127(3). 
 
Conclusion 
Three low energy structures were predicted for the orphan GPCR GPR88.  
These predicted structures had an aliphatic binding pocket in the TM2-TM3-TM6-
TM7 region that would likely bind to an aliphatic lipid tail.  The head group of a 
lipid could bind to R113(3) and R116(3) at the extracellular side of the receptor.  
Three lipids that commonly bind to GPCRs were docked: S1P, LPA and FFA.  
The predicted bound structures show that all three lipids would likely bind to 
GPR88, with the head group forming hydrogen bonds to R113(3) and R116(3).  
The residues contributing favorably to the binding of the lipid tails are L120(3), 
L124(3), W84(2), W322(7), C325(7), L305(6), S321(7), L328(7), V301(6), and 
S127(3), in order of decreasing predicted strength of interaction.  Mutagenesis 
experiments on these residues could help to indirectly confirm the validity of one 
of the predicted GPR88 structures. 
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